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Altered lipid metabolism is a recognized contributor to neurodegenerative (ND) 
conditions, both rare and common, such as Adrenoleukodystrophy (ALD) and 
Alzheimer’s disease that affect millions of individuals worldwide.  For most of these 
diseases, therapeutic options are limited. Significant therapeutic progress might be 
expected with the development of animal models. Two Drosophila mutants fail to 
activate long- and very long-chain FAs (acyl CoA-synthetases, ACS) were used to probe 
the relationship between lipid homeostasis and nervous system function with the 
overarching goal of determining the primary cell type affected, and the specific 
subcellular defect in an animal model for ALD (Figure 1.1 A, B).   Adults homozygous 
for mutations in bubblegum (bgm) or double bubble (dbb) exhibit increased very long 
chain FA levels, a distinguishing feature of this human disease. The observed deficiency 
in activation leading to ND could be due to an inability to clear precursor and/or to 
generate sufficient product. Herein, we demonstrate that dietary supplementation with 
medium chain FA rescues ND in dbb mutants and partially rescues bgm mutants. In 
contrast, diet studies designed to increase the demand for product while leaving an 
accumulation of precursor unchanged enhance ND. Alternate approaches utilizing  
light/dark cycles, and blocking elongation of VLCFAs, corroborate these results 




mutants. These data provide support to the observations that therapies designed to reduce 
toxic accumulations in patients with ALD are ineffective and instead suggest an alternate 
approach to providing the missing product. Consistent with this notion is our 
identification of a leukodystrophy patient harboring a rare mutation in a human homolog 
of bgm. Additionally this patient harbors a mutation in a known epilepsy gene suggesting 
that stress, by use or by trauma, may precipitate ND in an ACS mutant background. 
These data provide candidates for the long-hypothesized gene-gene and gene-
environment interactions proposed with ALD by identifying new genes (ACSs), 
mechanisms (lack of product), and environments (trauma, seizures) that contribute to 
disease. More broadly, these studies enhance our understanding of the required roles of 

















































Nature composes some of her loveliest poems for the microscope and the telescope.  
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Leukodystrophy pathology and ALD 
Leukodystrophies are a class of degenerative diseases that affect the white matter 
of the brain and have a broad-ranging age of onset with varying life expectancies 
(Gordon et al., 2014).  Diagnosis is achieved by detection of abnormal white matter in the 
brain via MRI scans, usually after an accompanying neurological symptom warrants a 
visit to a clinician (issues with balance, sight, seizures, etc.).  A leukodystrophy diagnosis 
is devastating as there are no known treatments for any form of leukodystrophy (Gordon 
et al., 2014; van der Knaap et al., 1999).  Additionally, approximately half of individuals 
who present with this life-threatening clinical diagnosis do not resolve to a clear cause, 
underscoring the need to identify the genes responsible for leukodystrophy (Bonkowsky 
et al., 2010; van der Knaap et al., 1999).  
Adrenoleukodystrophy (ALD), one of the most common leukodystrophies, is a 
rare and fatal neurodegenerative disorder with no known cure (Bonkowsky et al., 2010; 
Helman et al., 2015).  The most common form of ALD occurs through inheritance of 
loss-of-function alleles of ABCD1 on the X-chromosome (X-ALD).  Therefore, the 
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condition usually occurs in males, most often between the ages of 5-8 (Moser et al., 
2005b; Engelen et al., 2012; Kim and Kim, 2005).  Females are carriers and transmit a 
mutated ABCD1 allele to children, but they themselves only sometimes show a 
phenotype due to mosaicism in X-inactivation (Hershkovitz et al., 2002; Maier et al., 
2002).   
 ALD occurs in approximately 1:17,000 births across all ethnicities, and 
inheritance of null alleles in ABCD1 leads to incompletely penetrant and variably 
expressed phenotypes, making age of onset and severity of symptoms difficult to predict 
in males with ABCD1 mutations (Moser et al., 2005b).  Symptoms often begin with 
deteriorating vision, volatile behavior, hyperactivity, and decreased motor function, and 
progress to coma or death within a few years of diagnosis.  In addition to MRI, clinicians 
specifically diagnose ALD by testing for an increase in very long chain fatty acids 
(VLCFAs) in blood and DNA sequencing of the ABCD1 gene (Steinberg et al., 1993).  
ALD phenotypes are variably expressed (see Figure 1.2 A).  Forty percent of 
patients inheriting null alleles of ABCD1 exhibit the most severe form of the disease 
(cerebral ALD) affecting the central nervous system and involving a significant 
inflammatory component and progressive demyelination.  A second patient group (40-
45%) will escape this early childhood phenotype and instead present in the second to 
fourth decade of life with a less severe but nonetheless debilitating form of the disease 
involving the peripheral nervous system (Adrenomyeloneuropathy, AMN).  
Approximately 10% of individuals will experience only adrenal insufficiency (Addison’s 
Disease) and no nervous system component (Engelen et al., 2012; Steinberg et al., 1993). 
ALD phenotypes are also incompletely penetrant (Figure 1.2 A).  Ten percent of 
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individuals, harboring a null allele identical to that of an affected individual, even a 
family member, exhibit neither nervous system deficiencies nor adrenal gland 
insufficiencies.  Such variation in penetrance and expressivity has led many to 
hypothesize the existence of environmental and genetic modifiers of ALD that if 
identified could assist in prediction of disease phenotype and development of therapeutic 
avenues (Moser, 1997; Wiesinger et al., 2015).  In Chapters 2 and 3 I describe my 
identification of components of the VLCFA activation pathway that appear to be required 
for maintenance of neuronal health in both flies and humans.  Our fly model of ALD is 
important because it provides a medium throughput platform for screens for the 
identification of additional genes functioning in VLCFA metabolism and in central 
nervous system maintenance and health. 
 
ALD genetics 
The gene responsible for X-ALD has been cloned and shown to encode a 
peroxisomal half ATP-binding-cassette transporter (ABCD1: ATP-binding cassette, sub-
family D [ALD], member 1, formerly ALDP) (Mosser et al., 1993). Mutations in this 
gene, the only gene linked to ALD, are present in affected individuals but do not 
guarantee a disease phenotype (Wiesinger et al., 2015).  Males pass their X-chromosome 
on to their daughters, and thus males hemizygous for a mutated ABCD1 allele will 
transmit this allele to all of their daughters.  For those heterozygous daughters, the 
probability of transmission of the pathogenic allele is then 50% for all offspring—males 
or females. de novo mutations in ABCD1 have been characterized (Bezman et al., 2001; 
Wang et al., 2011b) and de novo mutation rates are estimated to be around 4%, although 
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the highest predictions have approached 20% (Wang et al., 2011b; Horn et al., 2013).  A 
comprehensive list of all ABCD1 mutations is publically available (http://www.x-ald.nl).   
 
Very long chain fatty acids in ALD 
Fatty acids are carboxylic acids with the “R” group consisting of a linear carbon 
chain that can very in saturation with hydrogen atoms as well as in overall chain length.  
The carboxylic acid can be chemically modified for various cellular purposes such as 
conjugation to a glycerol molecule and hydrophilic phosphate group to generate a 
phospholipid.  In this manuscript, “very long chain fatty acids” refers to all carboxylic 
fatty acids with a carbon chain length of 22 carbons and greater, as well as their 
subsequently modified versions (such as in phospholipids). 
ABCD1 encodes a peroxisomal half-transporter (Mosser et al., 1993).  The current 
hypothesis for the mechanism of neurodegeneration in ALD states the ABCD1 protein 
(also called ALDP: Adrenoleukodystrophy Protein) is required for import of VLCFAs 
into peroxisomes where initial steps of oxidation occur: The absence of ABCD1 leads to 
a an accumulation of VLCFAs within tissue that is believed to be causative of cell death.  
This model is built on observations of accumulation of saturated VLCFAs—a well 
known biochemical hallmark of X-ALD (Igarashi et al., 1976).  All X-ALD patients 
show elevated levels of VLCFAs, in particular- tetracosanoic acid (C24:0) and 
hexacosanoic acid (C26:0) in the plasma, brain, and adrenal gland.  There is more recent 
evidence for the additional accumulation of monounsaturated VLCFAs in plasma and 
fibroblasts of X-ALD patients (Kemp et al., 2005).   
Given this association between disease state and VLCFA accumulation, the 
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relevance of such an increase in VLCFAs has been under investigation but has led to 
unclear conclusions.  In multiple reports, exposure of both glial and neuronal cells to an 
increase in VLCFAs in culture is sufficient to induce mitochondrial dysfunction and cell 
death (Hein et al., 2008; Baarine et al., 2012; Mosser et al., 1993; Ronicke et al., 2009).  
The majority of these studies have been executed ex vivo, however, and it remains to be 
determined whether VLCFAs themselves play a central role in causing 
neurodegeneration in an in vivo model of ALD as well as whether this accumulation is 
necessary for neurodegeneration or simply a marker of the biochemical defect.   
Despite the appeal of toxic accumulation models for disease, a few pieces of 
evidence do not align with the idea that neurodegeneration is solely due to an 
accumulation of VLCFAs.  First 20% of individuals harboring disease-causing alleles of 
ABCD1 while exhibiting a fully penetrant increase in VLCFAs do not display any 
nervous system degeneration at all (Raymond et al., 2010; Weller et al., 1992; Moser et 
al., 1999; Steinberg et al., 1993) (displayed in Figure 1.2 B).  That these individuals do 
not manifest a neurodegenerative phenotype despite an accumulation of VLCFA equal to 
that in affected individuals suggests that VLCFA accumulation by itself is not causative 
of neurodegeneration.  Consistent with this idea is the observation that VLCFA levels do 
not correlate with the degree of neurological disability (Moser, 1997).  Second, animals 
with targeted disruption of the mouse ABCD1 gene exhibit (like humans) an increase in 
VLCFAs in affected tissues without an associated central nervous system phenotype 
reminiscent of ALD (Forss-Petter et al., 1997; Fourcade et al., 2009; Kobayashi et al., 
1997; Lu et al., 1997; Yamada et al., 2000).  The most severe phenotype ABCD1 null 
animals display is an incompletely penetrant AMN-like phenotype affecting the 
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peripheral nervous system only in aged animals (Dumser et al., 2007; Pujol et al., 2002).  
Third, although the sample size is low (2 patients), recipients of hematopoietic stem cell 
gene therapy showed a marked improvement in neurological symptoms despite plasma 
VLCFA concentrations remaining significantly high (Cartier et al., 2009).  Taken 
together, these data suggest that VLCFA concentrations in ALD represent a biomarker of 
neurodegeneration, but have little relevance to the mechanism of neurodegeneration.  
 
ACSs, ABCD1, VLCFAs, and the link to ALD 
Acyl-CoA synthetases (ACSs), which function immediately upstream of ABC 
transporters in activating fatty acids and effecting their peroxisomal degradation, have 
also been implicated in ALD disease pathology (Hashmi et al., 1986; Lazo et al., 1988; 
Wanders et al., 1988a). Biochemically active acyl-CoA esters are derived from 
chemically inactive precursors (free fatty acids) in a two-step process, and it is the 
activated fatty acid that serves as substrate for the ABCD1 transporter (see Figure 1.3 A) 
(Kemp et al., 2011).  There are four recognized ACS enzyme families: those activating 
short (2-3 carbons), medium (4-12 carbons), long (12-21 carbons), and very long (>22 
carbons) fatty acid substrates.  Although substrate specificity defines these families, it is 
common for specificities to overlap between families, particularly with respect to the 
long- and very long-chain substrates (Lu et al., 2009; Steinberg et al., 1993; Watkins, 
2008; Watkins et al., 2007).  
The essential role of ACSs in fatty acid metabolism is supported by their high 
degree of conservation in organisms ranging from bacteria to humans.  Before ABCD1 
was discovered as the gene causative of X-ALD, an ACS was predicted by many to be 
 7 
the gene at fault due to the marked decrease in ACS activity in patient samples (Hashmi 
et al., 1986; Lazo et al., 1988; Wanders et al., 1988a).  It seems clear now that ABCD1 
and some ACSs require one another’s presence for proper protein function.  Physical 
interaction between ABCD1 and a cellular very long chain ACS (ACSVL1) has been 
demonstrated in multiple contexts. ABCD1 requires the activity of ACS esterification of 
fatty acids in order to transport its lipid substrate (van Roermund et al., 2008).  Likewise, 
ACSVL1 requires ABCD1 to associate with the peroxisomal membrane and activate fatty 
acids for β-oxidation (Yamada et al., 1999).  One study using ABCD1-deficient 
fibroblasts showed that ACSVL1 expression can, in fact, rescue the β-oxidation 
deficiency seen in these cells but only when it is peroxisomally-localized (as opposed to 
ER-localizated) implying that the subcellular localization of ACSVL1 is imperative to its 
function and ABCD1 may assist in the correct peroxisomal targeting (Heinzer et al., 
2002).  Associations between ACSVL1 and ABCD1 have also been identified 
independently in yeast-two hybrid screens and surface plasmon resonance (Makkar et al., 
2006).  Thus, as Min and Benzer inferred after their identification of neurodegeneration 
in bgm homozygotes, ACSs and ABCD1 mutations exhibit shared-loss-of-function 
phenotypes because they both participate in the ACSL pathway (Min and Benzer, 1999a).  
In Chapter 2, I report identification of a leukodystrophy patient who harbors a likely 
disease-causing variant of SLC27a6, a gene encoding an ACS in humans.  Thus it appears 
that in humans, loss-of-function mutations in both ABCD1 and SLC27a6 lead to a shared 
loss-of-function neurodegenerative phenotype.  I show in Chapter 3 that RNAi targeting 
the Drosophila ABCD1 locus similarly leads to a shared neurodegenerative loss-of 
function phenotype with bgm and dbb mutants.  Finally, I hypothesized that other 
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members of ACSL pathway are involved in neuronal health and maintenance.  In this 
regard, my demonstration that Drosophila elongase mutants also exhibit the 
neurodegenerative shared loss-of-function phenotype is consistent with a requirement for 
ASCL pathway products in neuromaintenance. 
 
Modifier genes in ALD 
Although hundreds of ABCD1 alleles have been described, no genotype-
phenotype correlation has emerged, and inheritance of the same allele within a kindred or 
even shared between monozygotic twins can lead to different phenotypes (Berger et al., 
1994; Korenke et al., 1996).  Studies to identify modifying loci using either 
association/segregation studies or through gene expression analysis have had limited 
success due to the low number of individuals available for each study (Moser et al., 1992) 
(Wiesinger et al., 2015).  Nonetheless, a few gene candidates are worth mentioning.  
Biochemically, ABCD2 and ABCD3 (also known as ALDRP and PMP70, respectively) 
can compensate for the decrease in B-oxidation due to the loss of ABCD1 when 
overexpressed in ABCD1-deficient patient fibroblasts (Netik et al., 1999).  Additionally, 
in vivo overexpression of ABCD2 in ABCD1-deficient mice rescues an age-dependent 
AMN-like phenotype (Pujol et al., 2004).  In contrast, two independent association 
studies attempting to link variants in ABCD2 (Maier et al., 2008) and ABCD3, and 
ABCD4 with prevalence or severity of ALD have yielded no correlations (Matsukawa et 
al., 2011).  Association studies have identified two genes (HLA and SOD2) expressed in 
immune tissue that have been found to correlate with cerebral ALD but not with AMN or 
nonpenetrant ALD hemizygotes.  These genes are thought to play a role in disease 
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severity in an individual already harboring an ABCD1 mutation.  Human leukocyte 
antigen (HLA) is an MHC class gene required for recognizing self vs. nonself and 
initiating activation of immune cells.  Superoxide dismutase 2 (SOD2) is a mitochondrial 
protein that neutralizes damaging super oxide (O2-) into oxygen and H2O2.  Superoxide is 
increased at sites of inflammation.  It and H2O2 act as chemokines to attract and activate 
immune cells (Petrone et al., 1980; Kaminski et al., 2012).  Therefore, SOD2 plays an 
important role in balancing the damaging effects of reactive oxygen with recruitment of 
the immune response.  That the only genes that have been identified to play a role in 
ALD expressivity are immune-related genes speaks to the importance of the immune 
system in rapid progression of demyelination.  Although this is an important lesson, it 
represents only a small step in understanding how ABCD1 is required for 
neuromaintenance. 
 
ALD animal models 
Multiple attempts to generate mouse models that recapitulate central nervous 
system degeneration have been carried out in an effort to gain a tool to resolve the 
clinical heterogeneity of ALD.  Similar to human disease, ABCD1 knockout phenotypes 
appear to depend on genetic background.  In one case, targeted disruption of mouse 
ABCD1 in a C57BL/6 strain leads to the accumulation of VLCFAs in the CNS thereby 
recapitulating the biochemical abnormality seen in ALD patients.  However, mutant mice 
experience a normal life span and exhibit no signs of degeneration in either the CNS or 
PNS (Forss-Petter et al., 1997).  Knockout of ABCD1 in a different genetic background 
(strain 129/Sv), however, leads to accumulation of VLCFAs and development of age-
 10 
dependent (but incompletely penetrant) AMN-type symptoms (Lu et al., 1997; Pujol et 
al., 2002).  It is important to note that the genetic targeting strategies were very similar 
between these two reports as both replaced early regions of the gene (exon 1 and exon 2, 
respectively) with a neomycin resistance cassette resulting in an early termination gene 
product.  Attempts at modeling ALD by genetic disruption of another gene—VLCS-1 
(VLCFA acyl-CoA synthetase)—also resulted in mice with no neurological or 
biochemical defects possibly due to redundancy in metabolic enzymes (Heinzer et al., 
2003).  Although the establishment that genetic background plays a role in phenotype 
presentation is a valuable lesson, the utility of mouse knockout models has been hindered 
by the lack of a central nervous system phenotype, thus impairing the identification of 
genes involved in cerebral ALD. 
Utilizing a fly model to study ACS function is more telling, however, as mutation 
of the bubblegum (bgm) gene, encoding a Drosophila long chain ACS (ACSL) with 
predicted long- and very long-chain substrate specificities results in an autosomal 
recessive neurodegenerative phenotype (Min and Benzer, 1999a).  The bgm gene name 
refers to the appearance of a “bubbly” optic lobe in adult homozygous null mutants 
signifying a nervous system defect.  The reported neurodegenerative abnormalities are 
subtle but include disorganization of the optic lobe. Neurodegeneration is associated with 
small differences (not reaching statistical significance) in two saturated VLCFAs (C24 
and C26).  bgm flies have, therefore, not been embraced as a strong animal model for 
ALD.  In Chapter 2 we significantly improve the previous Drosophila ALD model by 
generating a double mutant animal harboring null alleles of bgm and its closest 
Drosophila homolog double bubble (dbb).  We show a more completely penetrant and 
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more severe neurodegenerative phenotype when the functions of both bgm and dbb are 
disrupted.  Analysis of retinal phenotypes in single and double mutants in addition to 
heterologous yeast studies to determine bgm and dbb biochemical function revealed an 
overlapping but not identical function of these two highly related genes.  In Chapter 3, we 
then use the individual single mutant animals to elucidate the biological roles of the 
ACSL pathway in the nervous tissue, revealing important lessons that provide insight into 
the mechanism of ALD pathology. 
 
Therapeutic approaches for ALD 
Therapies for ALD have been lacking.  A dietary treatment (popularized in the 
movie Lorenzo’s Oil) was developed to eliminate accumulated VLCFA levels in affected 
individuals (Rizzo et al., 1989).  However, this therapy was discontinued after multiple 
reports of its inefficacy and harmful effect on platelet levels in some patients (Moser, 
1999; van Geel et al., 1999; Zierz et al., 1993; Zinkham et al., 1993).   Currently, the only 
potentially effective therapy (bone marrow transplant) is applied to only the most severe 
cases, as this treatment is itself associated with a 20% mortality rate and degeneration is, 
at best, halted from progressing and not reversed (Aubourg et al., 1990; Shapiro et al., 
2000).  Experimental therapies using patient hematopoietic stem cells virally transduced 
with a functional copy of ABCD1 have been reported with some success.  However, this 
therapeutic approach has yet to be approved by the Food and Drug Administration in the 
United States (Cartier et al., 2009).  In the end, there are no currently feasible therapeutic 
options for ALD.  In Chapter 3, I revive the use of dietary therapy to understand the 
cellular defect leading to neurodegeneration in bgm and dbb animals.  This led to dietary 
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reduction in the age-progressive neurodegenerative phenotype, showing promise for 
future dietary therapeutic approaches in humans. 
 
Lipid Products 
Activation of lipids and shunting to specific functions 
The enzymatic reaction that ACSs control represents a crucial step of cellular 
lipid metabolism and act as gatekeepers for lipid bioavailability.  Lipid acylation by 
ACSs occurs in both the de novo lipid synthesis pathway and the reacylation pathway, 
which recycles lipids from other cellular uses.  Through this activation step, acyl CoA 
synthetases have historically been viewed as masters of lipid partitioning due to their 
ability to shunt lipids to a specific function within a cell (Coleman et al., 2002).  
Pharmacological studies using incomplete inhibitors of the ACS family have revealed 
these independent and specific roles of ACSs within a cell.  These observations were first 
made using the drug Triacsin C—a fungal-derived competitive ACS inhibitor (Tomoda et 
al., 1987).  The following studies take advantage of differences between de novo 
synthesis versus reacylation of lipids for the generation of triacylglycerol and 
phospholipid product.  De novo synthesis of these two lipid products incorporates 
glycerol in the form of glycerol-3-phosphate that serves as a backbone for which fatty 
acyl-CoAs can be attached.  Using recycled fatty acids for these lipid products via the 
reacylation pathway, however, does not incorporate glycerol, as lipid substrates in this 
pathway have already been modified.  When Triacsin C was applied to human skin 
fibroblasts, radiolabeled glycerol incorporation into phospholipid and triacylglycerol 
products was significantly blocked signifying disruption of the de novo pathway.  
 13 
However, when radiolabeled oleate was used to measure input of both the de novo 
pathway and the reacylation pathway into these lipid products, only the incorporation of 
oleate into triacylglycerol was blocked.  That oleate incorporation into phospholipids was 
intact suggests ACSs in the de novo pathway are separate from the reacylation pathway 
and that the latter ACS pool is triacsin C-insensitive and accounts for the majority of 
phospholipid product (Igal et al., 1997). Further observations of selective ACS inhibition 
have been confirmed and extended using in vitro methods (isolated rat hepatocytes and 
generation of recombinant protein) with triacsin C and a different drug, troglitazone 
(Fulgencio et al., 1996; Kim et al., 2001).  Of note, the mechanism of action of 
troglitazone on ACSs is through activation of PPARγ and not through competitive 
inhibition as it is with triacsin C, thus, not all ACSs lie downstream of PPAR activation 
(Lambe and Tugwood, 1996).  This idea of separate ACS pools is consistent with known 
subcellular localization patterns of different ACSs within the ER, mitochondrial, and 
microsomal membranes or floating freely in cytosolic pools (Coleman et al., 2000; 
Krisans et al., 1980; Lewin et al., 2001).  Although this observation is consistent with 
ACS pools with specific function, it is difficult to parse drug specificity from the 
possibility of drug partitioning in specific locations in the cell and therefore only acting 
on specific ACSs.  Additionally, ACSs have been found to display sometimes-
overlapping functions that complicate functional studies due to redundancy.  In Chapter 
2, we characterize the first genetic analysis of an ACS double mutant and through 
comparison of retinal phenotypes in single and double mutants, identify both independent 
and overlapping functions of the Drosophila ACSs bgm and dbb.  
Still, the ability of ACSs to shunt lipids into specific cellular functions has also 
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been investigated using gain- and loss-of-function studies can provide insight that cannot 
be explained by redundancy.  Overexpression of rat ACSL1 in primary hepatocytes 
channeled radiolabeled oleate into diacylglycerol and phospholipids, decreased 
incorporation into cholesterol esters and secreted triacylglycerol, and did not affect oleate 
incorporation into beta-oxidation, stored triacylglycerol, or total metabolized oleate (Li et 
al., 2006).  In adipose-specific disruption of ACSL1 in mice, a specific role of ACSL1 for 
shunting fatty acids into mitochondrial beta-oxidation is seen, although this specific result 
could be explained by redundant compensation of all other functions except shunting to 
beta-oxidation (Ellis et al., 2010).  Nonetheless, it displays a requirement for ACSL1 in 
shunting fatty acids into energy utilization pathways in adipocytes: whether this is the 
only function of ACSL1 remains to be determined.  In studies using human hepatoma 
cells, RNA interference targeting ACSL3 did not significantly decrease total ACS 
activity, but significantly affected radiolabelled oleate incorporation into 
phosphatidylcholine suggesting activation by ACSL3 shunts lipids into 
phosphatidylcholine synthesis (Yao and Ye, 2008).  Therefore, ACSs may still play a role 
in partitioning fatty acids into specific functions within a cell.  However, parsing a 
“shunting” role from redundant function in the ACS family of proteins must be 
considered for each case. 
 
The Fatp example of lipids required for function 
One landmark finding with particular relevance to the studies described in this 
dissertation is the discovery of a role of Drosophila fatp in neuromaintenance in the adult 
eye (Dourlen et al., 2012).  fatp—a membrane protein with dual functions as an acyl-CoA 
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synthetase and fatty acid transporter—was identified in a P-element screen to uncover 
genes required for photoreceptor differentiation, survival, and polarity—fatp is 
specifically required for neuromaintenance (Gambis et al., 2011).  Mosaic retinas with 
fatpk10307 clones experience age-dependent photoreceptor loss beginning around day 4 
post-eclosion and peaking around day 15 post-eclosion. Degeneration in these animals is 
cell-autonomous and rescued by neuronal expression of a dominant-negative rh1 allele 
(rh1G69D) and light dependent.  These data pointed to a neurodegenerative mechanism that 
is dependent on the phototransduction response in photoreceptors. In Chapters 2 and 3, 
we describe a strikingly similar neurodegenerative phenotype (with respect to age of 
onset, ultrastructural phenotype, and light dependency) in our ACS mutants.  The loss-of-
function phenotype shared by null alleles of fatp and the two ACS genes bgm and dbb 
suggest that the fatp mechanism of neurodegeneration is due to its function as an ACS 
and not as a fatty acid transporter.  In Chapter 4, I investigate whether rhodopsin 
recycling plays an integral role in the neurodegenerative phenotypes associated with loss 
of bgm and or dbb.   
 
Sources and uses of cellular VLCFAs 
ALD is thought to result from defects in processing very long chain fatty acids, as 
evidenced by the accumulation in plasma and affected tissues (Igarashi et al., 1976). We 
show in Chapter 2 that the long/very long chain family of lipids serves as substrates for 
the Drosophila Bgm and Dbb proteins.  Therefore, this dissertation will maintain a 
particular focus on the roles of the long/very long chain fatty acids.   
Fatty acids vary in chain length as well as saturation leading to a diverse 
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repertoire of lipids.  Consistent with tissue-specific roles for specific FAs within the cell, 
tissue compositions of FAs vary according to the tissue type (Carvalho et al., 2012; Sassa 
and Kihara, 2014).  As previously described, cells obtain fatty acids through one of two 
pathways (or a combination of both): 1) import and activation by cellular ACSs, or 2) 
modification of endogenous fatty acids by elongases (lengthen acyl chain) or desaturases 
(shorten acyl chain) (see Figure 1.3 B).  With regard to very long chain fatty acids 
(>C22), the relative contribution of each of these pathways to cellular concentrations is 
unknown and may additionally be tissue-specific.  Evidence exists that utilization of 
dietary fatty acids could account for a majority of VLCFAs in the brain.  However, the 
methods do not discriminate between the two sources above.  The only study focusing on 
the source of VLCFAs was performed on a terminally ill human subject by feeding 
radiolabelled VLCFAs and measuring incorporation of label in brain tissue upon autopsy 
(Kishimoto et al., 1980).  Ninety-six percent of the C26:0 fatty acids in the sampled brain 
tissue contained radiolabel.  This suggests dietary VLCFAs contribute to at least C26 
composition in vivo; however, due to the duration of time the patient was fed radiolabel 
(100 days), and the fact that radiolabel incorporation was only measured for C26 at a 
single timepoint, it is difficult to determine if these fatty acids were activated and used as 
C26, or if the radiolabelled fatty acids undergo multiple conversions to other fatty acid 
species and, in fact, account for 96% of all fatty acids (or other specific species) in the 
brain.  Dietary modulation of in vivo VLCFAs composition has also been documented in 
Drosophila (Carvalho et al., 2012).   
Despite knowledge of the existence of the very long chain class of fatty acids 
since the late 1980’s, VLCFAs have been fairly understudied.  Under recognition of 
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VLCFAs could be due to their low abundance in tissue isolates (~2% of retinal lipids) 
(Agbaga et al., 2010; Aveldano, 1987; Aveldano and Sprecher, 1987; Rotstein and 
Aveldano, 1988). The highest concentrations of VLCFAs are found in the testis, brain 
and retina (Agbaga et al., 2010). Despite low abundance, multiple lines of evidence point 
to the biological relevance of this class of fatty acids in at least some tissues.  This 
evidence is gleaned from mutant phenotypes in elongase genes that generate VLCFAs, 
suggesting that contribution from at least the second pathway above contributes 
significantly to total VLCFA levels. In mice lacking Elovl3 and Elovl1, skin barrier 
function is significantly compromised as a proposed consequence of altered L/VLCFA 
synthesis (Elovl3 -/- mice displayed decreased C16 and C18 and increased C20 whereas 
Elovl1 -/- mice displayed increased <C24 and decreased >C24) (Sassa et al., 2013; 
Westerberg et al., 2004).  Elovl3 mutant mice were susceptible to hypothermia after 
submersion in water.  Elovl1 mutant mice were lethal within 24 hours of birth.  
Drosophila mutants in the elongase gene bond show spermatogenesis defects due to an 
inability for furrow ingression during cytokinesis.  This is proposed to be due to an 
inflexibility of the plasma membrane to bend as the furrow progresses in the final stages 
of cell division (Szafer-Glusman et al., 2008).  Spermatogenesis defects are also seen in 
mice lacking Elovl2.  Both homozygous mutant as well as heterozygous animals have 
decreased VLCFAs C28 and C30 in the testis (Zadravec et al., 2011).  In humans, 
mutations in the ELOVL4 gene cause a rare form of macular dystrophy (Stargardt 
macular dystrophy 3)(Agbaga et al., 2010; Zhang et al., 2001).  Of note, inherited alleles 
are haploinsufficient as individuals heterozygous for ELOVL4 manifest disease that could 
either suggest a sensitivity of retinal cells to VLCFA levels or could be explained through 
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a feedback mechanism that down regulates expression.  Fitting with a requirement of 
VLCFAs in neuromaintenance, expression of ELOVL4 is high in photoreceptors of the 
mouse retina and increases with age until postnatal day 30 where it remains at a steady 
state level (Mandal et al., 2004).  These mutant phenotypes suggest a requirement in 
multiple tissues for VLCFAs, including the neuronal tissue of the retina.  
 
Defects in lipid metabolism are linked to  
neurodegenerative disease 
ALD stems from alterations in lipid homeostasis, as genetic variants in the lipid 
transporter ABCD1 are disease-causing in families with X-linked ALD, the only form of 
ALD with a tractable genetic cause.  Other nonleukodystrophy neurodegenerative 
diseases are caused by variants in genes encoding proteins that like ABCD1 play key 
roles in lipid metabolism (acid sphingomyelinase: Niemen Pick type A OMIM#257200, 
alpha-galatosidase A deficiency: Fabry disease OMIM#301500, and acid ceramidase: 
Farber’s disease OMIM#228000). Although all of these diseases are associated with an 
accumulation of lipid species, the mechanism of neurodegeneration is unknown (Ahmad 
et al., 2009; Madra and Sturley, 2010; Ries and Gal, 2006; Schiffmann, 2006; Vazquez et 
al., 2012; Zhang et al., 2000).  Fabry disease and Farber’s disease (like ALD) both 
display variable expressivity suggesting as-yet-unidentified genetic or environmental 
modifiers.  That these diseases, along with ALD and undiagnosable leukodystrophies, 
remain so poorly understood demonstrates the need for increasing our basic 
understanding for the roles lipids play in maintenance of the nervous system.  
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Cell Specificity in Neurodegenerative Diseases 
Cell autonomous and noncell autonomous mechanisms 
Determination of cell types affected in ALD opens the door to understanding 
diseases etiology and treatment.  Whether the cellular defect is autonomous in neuronal 
cells, or nonautonomous in glial cells, contributes a great deal to understanding the 
requirements of these cell types for neuromaintenance and by deduction, the mechanism 
of dysfunction in neurodegeneration.  Additionally, therapeutic protocols are depedent 
upon cell type(s) affected, as mechanisms for therapeutic delivery are unique for each 
(Drinkut et al., 2012). Both the glial and neuronal cell types that constitute the nervous 
system have been implicated in various neurodegenerative diseases.  Glia are fatty-rich 
support cells that have recently been recognized as playing an important role in 
Alexander’s Disease (Wang et al., 2011a), possessing the ability to perform immune-like 
function and required for general neuromaintenance (Liu et al., 2015; Mrak and Griffin, 
2005). However, it is the metabolically demanding neuronal cell types that have 
historically been studied as the primary cells affected in neurodegenerative diseases such 
as Alzheimer’s and Parkinson’s disease (Forloni et al., 1993; Mironov et al., 2003; 
Nikolaev et al., 2009; Obeso et al., 2010).  Overall, the relative contribution of each of 
these cell types is difficult to resolve in human patients (Barker and Cicchetti, 2014).  In 
ALD, there is little known concerning the primary cell type affected.  Some reports 
suggest that glial cells (most often oligodendrocytes and astrocytes) are dysfunctional in 
ALD patients or ex vivo upon increased VLCFA treatment (Aubourg and Dubois-Dalcq, 
2000; Di Biase et al., 2004; Feigenbaum et al., 2000; Katsuragi et al., 1996; Khan et al., 
1998) whereas others focus on the function of ABCD1 or ACSs in neurons (Pei et al., 
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2003).  Still, some studies suggest both neuronal cells and glia are dysfunctional (Hein et 
al., 2008).  The involvement of non-nervous system tissue also adds complexity to an 
already complicated disease, begging the need for a clean model in which to test tissue-
specific requirements of ACSL metabolism early in disease-progression.  The ability to 
test whether defects in either neurons or glia cause neurodegeneration in an in vivo ALD 
model has not been possible until recently (Sivachenko et al., 2015).   
 
Research Objectives 
Despite a growing understanding of ALD pathology and the identification of 
ABCD1 as a causative gene, the mechanistic role of ABCD1 in neuromaintenance 
remains to be definitively shown.  Further, effective disease-modifying therapies are not 
yet available. The work presented in this dissertation describes two approaches to address 
these challenges. The first objective is to define the timing and cell type critical for ALD 
neuropathology. In Chapter 3, I show that bgm deficient flies expressing a rescue 
construct solely in adult neuronal cells rescues neurodegeneration. Additionally, I show 
that dABCD1 knock down in neuronal cells but not glial cells results in a 
neurodegenerative phenotype.  The second objective is to determine the subcellular 
mechanism of neurodegeneration in bgm and dbb mutant animals. In Chapter 3, through 
the use of two dietary regimes, I differentiate between the ideas that a toxic accumulation 
of precursor or a lack of terminally processed lipid product leads to neurodegeneration.  I 
show that bgm and dbb mutant flies fed a diet high in fatty acids presumed to accumulate 
show no worsening of neurodegeneration, while those flies fed a diet containing fatty 
acids that can be converted to the terminally processed product show a significant rescue 
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of neurodegeneration.  I confirm these observations by artificially decreasing the cellular 
need for this terminally processed product by decreasing light exposure in adult bgm and 
dbb mutants and show a rescue of neurodegeneration in animals raised in constant 
darkness.  Finally, I test the requirement for this terminally processed lipid product by 
down regulating anther biochemical pathway used to obtain this product—the elongase 
pathway.  I show that animals harboring RNAi targeted to the elongase encoded by 
CG2781 share a neurodegenerative phenotype seen in other members of the ACSL 
pathway.  I interpret these results to suggest a revival of dietary therapy, and combined 
with further resolution of the specific cellular defect expect that a long-term outcome of 
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Figure 1.1 Scope of research objectives. The goals of this dissertation are to contribute 
to two fundamental questions centered around the use of fatty acids in the nervous system 
which represent untested questions in the field of ALD research. (A) The first is whether 
the primary cell type affected is a neuronal or glial cell, as these represent very different 
cellular populations with respect to etiology as well as therapies. (B) The second is 
identifying whether a buildup of precursor or a lack of activated fatty acid product results 
in the subcellular defect leading to dysfunction. 
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B. Subcellular defect: a lack of activated fatty acid product and not an
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Figure 1.2 Increased VLCFAs do not account for phenotypic presentation of ALD. 
(A) Spectrum of neurological phenotypes in patients with the most common cause of 
ALD—ABCD1 mutations—paired with (B) the percentage of patients displaying a 
significant increase in plasma VLCFA levels. Merging these pie charts highlights patients 









Figure 1.3 Obtaining activated fatty acids. (A) The family of Acyl CoA Synthetases 
biochemically activate fatty acids by esterifying the acyl chain with a coenzyme A. Only 
activated fatty acids are biochemically available for further modification and use within the 
cell. (B) Activated VLCFA product is obtained through two methods—activation of free 
VLCFAs by Acyl CoA Synthetases specific for long and very long chain fatty acids or 

































NEURODEGENERATION IN A DROSOPHILA MODEL OF 
ADRENOLEUKODYSTROPHY: THE ROLES OF THE  




Debilitating neurodegenerative conditions with metabolic origins affect millions 
of individuals worldwide.  Still, for most of these neurometabolic disorders there are 
neither cures nor disease-modifying therapies, and novel animal models are needed for 
elucidation of disease pathology and identification of potential therapeutic agents.  To 
date, metabolic neurodegenerative disease has been modeled in animals with only limited 
success, in part because existing models constitute analyses of single mutants and have 
thus overlooked potential redundancy within metabolic gene pathways associated with 
disease.  Here we present the first analysis of a very long chain acyl-CoA synthetase 
double mutant.  We show that the Drosophila bubblegum (bgm) and double bubble (dbb) 
genes have overlapping functions, and that the consequences of bubblegum double 
bubble double knockout in the fly brain are profound, affecting behavior and brain 
morphology, and providing the best paradigm to date for an animal model of 
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Adrenoleukodystrophy (ALD), a fatal childhood neurodegenerative disease associated 
with the accumulation of very long chain fatty acids.  Using this more fully penetrant 
model of disease to interrogate brain morphology at the level of electron microscopy, we 
show that dysregulation of fatty acid metabolism in vivo is causal of neurodegenerative 
pathologies evident in both neuronal cells and their support cell populations, and leads 
ultimately to lytic cell death in affected areas of the brain.  Finally, in an extension of our 
model system to the study of human disease, we describe our identification of a 
leukodystrophy patient who harbors a rare mutation in SLC27a6, a human homologue of 





Adrenoleukodystrophy (ALD) is a rare and oftentimes fatal progressive 
neurodegenerative disease.  The most common form of the disease is X-linked (X-ALD) 
with an estimated incidence of 1:17,000 in all ethnic groups.  X-ALD is a clinically 
heterogeneous disorder, exhibiting incomplete penetrance and variable expressivity 
(Moser et al., 2005a).   
The most severe form of X-ALD, affecting ~40% of all patients, is cerebral ALD.  
Demyelination in the central nervous system (CNS) constitutes the major burden of 
cerebral ALD, with the disorder most frequently diagnosed as progressive neurological 
dysfunction in previously healthy boys between the ages of 4 and 8 years old.  A less 
severe, but nonetheless debilitating, form of the disease (Adrenomyeloneuropathy 
[AMN]) occurs in ~40% of X-ALD patients.  In AMN patients, demyelination is 
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confined (at least initially) to the peripheral nervous system (PNS).  AMN patients 
present in the second to fourth decade of life with impotence, sphincter dysfunction, and 
slowly progressive paraparhesis.  About 10% of X-ALD patients have adrenal 
insufficiency without nervous system involvement; a similar small number of males 
remain entirely asymptomatic.  It is notable that wide phenotypic variability is observed 
within kindreds segregating the same mutation; thus, environmental and/or genetic 
factors must play significant roles as disease modifiers (Moser, 1997). 
 
Function of the ATP-binding-cassette transporters in ALD 
The gene responsible for X-ALD has been cloned and shown to encode a 
peroxisomal half ATP-binding-cassette transporter (ABCD1: ATP-binding cassette, sub-
family D [ALD], member 1) (Mosser et al., 1993).  The 745 amino acid ABCD1 protein 
(or ALDP: Adrenoleukodystrophy Protein) localizes to the peroxisomal membrane, 
where like other members of the ABC (ATP-binding cassette) transporter family, it 
functions to transport very long chain fatty acids (VLCFAs, 22 or more carbons) via their 
acyl-CoA esters into peroxisomes where they are degraded by ß-oxidation (Fig. 1A).  
Indeed, accumulation of saturated VLCFAs is a known biochemical hallmark of X-ALD 
(Igarashi et al., 1976).  All X-ALD patients, including asymptomatic carriers, show 
elevated levels of VLCFAs, in particular tetracosanoic acid (C24:0) and hexacosanoic 
acid (C26:0) in the plasma, brain, and adrenal gland.  There is more recent evidence for 
the additional accumulation of monounsaturated VLCFAs in plasma and fibroblasts of X-
ALD patients (Kemp et al., 2005).  This finding has especially important consequences 
with respect to treatment of individuals with the highly controversial Lorenzo’s oil, itself 
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a mixture of mono–unsaturated VLCFAs. 
 
Function of very long chain acyl-CoA synthetases in ALD 
Acyl-CoA synthetases (ACSs), which function immediately upstream of ABC 
transporters in effecting peroxisomal degradation of fatty acids, have also been 
implicated in ALD disease pathology (see Fig. 2.1A).  Chemically-reactive fatty acyl-
CoA esters, which are derived from their chemically-inactive precursors (free fatty acids) 
in a two-step process, serve as substrate for the ABCD1 transporter.  It is the second step 
of the fatty acid esterification process that is catalyzed by ACS.  There are four 
recognized enzyme families with ACS activity, those activating short (2-5 carbons), 
medium (6-12 carbons), long (13-21 carbons), and very long (≥22 carbons) fatty acid 
substrates.  Although families are defined by substrate specificities, it is common for 
these to overlap between families, particularly with respect to the long- and very long-
chain substrates (Lu et al., 2009; Steinberg et al., 1999; Watkins, 2008; Watkins et al., 
2007). The essential role of ACSs in fatty acid metabolism is supported by their high 
degree of conservation in organisms ranging from bacteria to humans.  ACSs are defined 
by two highly conserved functional domains: the 10 amino acid AMP–binding domain 
and the 35 amino acid signature motif that plays an integral role in determining substrate 
specificity (Watkins, 2008).   
 
Animal models of ALD 
Investigators have long sought to resolve the clinical heterogeneity of ALD in 
animal models, thus far however with only very limited success.  Phenotypes associated 
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with knockout of ABCD1 in mouse are dependent upon genetic background.  In one 
ABCD1 knockout mouse model of X-ALD, mice experience a normal life span and 
exhibit no signs of degeneration in either the CNS or PNS.  The same knockout in a 
different genetic background, however, does lead (albeit at low frequency) to 
accumulation of VLCFAs and development of AMN-type symptoms (Forss-Petter et al., 
1997; Lu et al., 1997).  With regard to ACS loss-of-function, neither neurological defects 
nor VLCFA accumulation is detected in VLCS-1 (VLCFA acyl-CoA synthetase) 
knockout mice (Heinzer et al., 2003).   
Data obtained in a fly model of ACS function are more encouraging, as mutation 
of bubblegum (bgm), the gene encoding a Drosophila long chain ACS (ACSL) with 
predicted long- and very long-chain substrate specificities results in an autosomal 
recessive neurodegenerative phenotype (Min and Benzer, 1999b).  bgm homozygotes 
exhibit impaired vision and a “bubbly” optic lobe, phenotypes resulting from a loss of 
nervous tissue.  The documented bgm-associated biochemical and neurodegenerative 
abnormalities are subtle, being limited to moderate accumulation of two saturated 
VLCFAs and minimal disorganization and degeneration of the optic lobe.  bgm flies 
have, therefore, not been embraced as a strong animal model for ALD.   
Until now, what none of the ABC transporter or ACS animal studies (neither fly 
nor mouse) have adequately contemplated is the considerable potential for redundancy 
within these gene families.  With regard to the latter, although original classifications of 
the acyl-CoA synthetases were based solely on the fatty acid chain lengths of their 
substrates, more recent studies point to overlapping substrate specificities (Watkins, 
2008; Watkins et al., 2007).  Indeed, having confirmed that the bgm allele used by Min 
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and Benzer (1999b) is a null, we show here that a far more profound phenotype, and thus 
a better ALD disease model, is found in double mutant animals harboring mutations not 
only in the bgm-encoded ACSL, but also in its homologue the double bubble (dbb)-
encoded ACSL. 
As described in this report, our focus on the similarities between bgm dbb and 
ALD phenotypes provides new insights into defects associated with accumulation of 
VLCFAs.  In particular, we show that defects in VLCFA metabolism affect neurons as 
well as their support cells, and lead to widespread cell losses in the fly brain.  In addition, 
our detection of inclusions in bgm dbb mutant flies augurs an attractive diagnostic tool.  
Underscoring the relevance of ACSL mutations to ALD phenotypes, we also describe our 
identification of a young boy with an undiagnosed leukodystrophy harboring a mutation 
in SLC27a6, a dual ACSL/fatty acid transporter with homology to Bgm and Dbb. 
 
Materials and Methods 
Fly stocks 
Balancers, Canton S, w1118 and Df(bgm) (Df(2L)b87e25/CyO [34B12-
C1;35B10-C1]) have been described (FlyBase, 2003).  bgm1 was from K-T. Min 
(NINDS).  Strains for targeted mutagenesis were from K. Golic (Univ. of Utah).  
 
Targeted mutagenesis 
Ends-out gene targeting was performed as described (Gong and Golic, 2003).   
Our targeting construct was engineered to delete the 5’ two-thirds of the dbb coding 
region.  To this end, DNA fragments corresponding to 14023363-14026942 and 
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14028337-14031358 in the Drosophila melanogaster genome were subcloned into the 
pW25 plasmid.  Targeting was verified in progeny by PCR (using 5’-
CGAAAGGGAGAGTTCGACTCC and 5’-GGC TGCTGCAATAAGATTAGGGC 
primers) and by RT-PCR (using 5’-CGGATATCACACTGTCAC and  5’-
CATCGGCATACATCTTGGACA for bgm, 5’-GCCATCATCCTTTTCACAGAC and 
5’-GTACAGACGCTCGATGACTTTG for dbb, and  5’ 




BY4743 strains mutant for the yeast genes FAA1 and FAT1 (the generous gift of 
Diane Ward Univ. of Utah) were transfected with constructs containing Drosophila bgm 
or dbb cDNAs cloned into the yeast expression vector p426-ADH1.  Yeast cultures were 
grown on YPD (yeast peptone dextrose; standard growth medium) supplemented with 
cerulenin (Cayman Chemical, Ann Arbor, MI) to inhibit de novo synthesis. Oleate and 
myristate were obtained from Nu Check Prep (Elysian, MN).  G418 selection was 
employed to monitor the FAA1 and FAT1 mutant backgrounds and 5-FOA to monitor 
the p426-ADH1 vector.  
 
Activity and lifespan studies 
Wild-type and mutant flies were maintained in a 12h:12h light:dark cycle at 25°C.  
For activity phenotyping, 6-18 males/genotype were individually transferred to monitor 
tubes on the day of eclosion, and to fresh tubes weekly.  Locomotor activity was 
 48 
monitored using the Drosophila Activity Monitoring System starting within 24 hours of 
eclosion and continuing each week until day 30 post-eclosion (Trikinetics, Waltham, 
MA).  Average peak activity was determined by analyzing beam break occurrences 
during the 2 hours before and after light change after acclimatization into the activity 
chambers.  For longevity studies, 40-100 flies/genotype were seeded at an initial density 
of 20 flies/vial.  Survivors were transferred to fresh vials every 7 days. Curves are 
estimated from the results of three independent trials.  Graphpad Prism software was 
employed for statistical analyses. 
 
Histology and transmission electron microscopy 
For histological examination, heads were dissected and processed as described 
(Palladino et al., 2002).  Serial 6-µm sections were stained with hematoxylin and eosin, 
and scored blindly under a light microscope for the presence of vacuoles with diameter 
greater than 3 µm, retinal degeneration, and fenestrated membrane changes.  For TEM 
studies, heads were embedded in Spurr’s epoxy resin, sectioned at 70-90 nm thickness 
using a Reichert-Jung Ultracut E microtome, postfixed with osmium and stained with 2% 
uranyl acetate and Reynolds’ lead citrate.  Ultrastructural analysis was carried out using a 
Hitachi H-7100 electron microscope at 125 kV. 
 
Fatty acid profiling 
Extracts from 18-day-old  males and females were used for purification and 
methylation of fatty acids.  Solutions were analyzed by GC-MS  using a Micromass GCT 
Premier time-of-flight mass spectrometer fitted with an Agilent 6890 gas chromatograph 
 49 
and autosampler (Waters Corp., Beverly, MA).   
 
Patient analysis 
The Institutional Review Boards of the University of Utah and Intermountain 
Healthcare (IH) approved this work. Clinical exome sequencing was performed through 
Baylor Medical Genetics Laboratories.  Confirmatory Sanger sequencing for SLC27a6 
was performed using primers (5’-3’): TGAGCAAACATGTTCTAGACAGAG and 
reverse-TACCTTTGTTACTGGCGGGT.  Template DNA was isolated from cheek cells 
in all individuals shown in the pedigree. 
 
Results  
bgm and dbb encode duplicated Drosophila  
acyl-CoA synthetases 
Our studies have their foundation in the postulate that acyl-CoA synthetases in 
Drosophila have overlapping and hence sometimes redundant function.  In this regard, 
there are multiple ACSs in all species.  In Drosophila, in addition to bgm, there are seven 
genes encoding fatty acid acyl-CoA synthetases (Fig. 2.1B).  bgm and CG4500 
(designated here as double bubble [dbb]) are more closely related to one another than 
they are to the other members of their family.  bgm and dbb share 43% identity and 62% 
similarity at the amino acid level.  Furthermore, bgm and dbb map immediately adjacent 
to one another in the Drosophila genome (7.7 kb apart; Fig. 2.1C). The bgm and dbb 
genes belong to the evolutionarily well-conserved Bgm family of ACSLs.  The human 
homologue (hBgm) is 41% identical (61% similar) to Drosophila Bgm, and 37% 
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identical (55% similar) to Drosophila Dbb (supplementary material Fig. 2.S1). 
 
The bgm and dbb gene products retain their predicted  
acyl-CoA synthetase activity 
To test whether the bgm and dbb gene products retain their predicted acyl-CoA 
synthetase activity, as well as to determine whether they possess the additional fatty acid 
transport function that defines the related FATP family of dual functioning enzymes, we 
assessed bgm and dbb activity in a yeast heterologous system.  Expression of either the 
bgm or dbb Drosophila cDNA in an S. cerevisiae strain that is null for Faa1p (the major 
ACSL in yeast) restored strain viability in the presence of the de novo fatty acid synthesis 
inhibitor cerulenin when myristate was added to the culture medium; only bgm, however, 
rescued in the presence of oleate (Fig. 2.1D).  (Both myristate and oleate represent long-
chain fatty acids, C14:0 and C18:1, respectively).  In contrast, neither Drosophila cDNA 
was able to rescue Fat1p (fatty acid transporter) -dependent lethality in the presence of 
cerulenin (data not shown).  Thus, while both bgm and dbb retain acyl-CoA synthetase 
activity and exhibit overlapping substrate specificities, neither is dual functioning.  The 
latter finding was somewhat unexpected as mouse ACSL1 (mouse Bgm) restores not only 
fatty acid activation to Faa1p-deficient yeast but also fatty acid uptake to Fat1p mutants, 
indicating a concordance of activation and uptake functions in this enzyme (DiRusso et 





Knocking out bgm and dbb gene functions 
Extensive Bgm/Dbb homology at the protein level, as well as their overlapping 
substrate specificities led us to speculate that the bgm and dbb-encoded ACSL functions 
are redundant.  We tested this hypothesis in genetic analyses of single and double 
mutants.  We used the previously characterized bgm1 null allele for our study, but turned 
to targeted knockout methods to generate the dbb1 null allele and the bgm1 dbb1 double 
null mutant (Fig. 2.2A).  PCR analysis allowed discrimination of wild-type and mutated 
loci based on a 3.3 kb fragment differential at the dbb1 locus (Fig. 2.2B).  Measurement 
of transcript levels in wild-type and mutant animals revealed traces of bgm mRNA in 
the previously-characterized bgm1 null background, but no detectable dbb mRNA in the 
genetically-engineered dbb1 null (Fig. 2.2C). 
 
bgm and dbb function redundantly in the adult CNS 
To study the functional relationship between bgm and its homologue dbb in 
maintenance of adult CNS integrity, we analyzed brain morphologies in wild-type flies, 
and in single and double mutant flies.  For histological studies, heads from 18-day-old 
wild-type (Canton S) and mutant (bgm1, dbb1 and bgm1 dbb1) flies were embedded in 
paraffin, stained with hematoxylin and eosin, and scored blindly under a light microscope 
for the presence of: (a) optic ganglion (laminal) holes with diameters greater than 3 µm, 
(b) retinal disorganization, and (c) fenestrated membrane loss.  While the optic ganglion 
phenotype was quantified by hole number, the degree of retinal degeneration was scored 
qualitatively as 1 for normal appearance, 2 for mild tissue loss, 3 for moderate 
degeneration, and 4 for severe degeneration.  For the assessment of fenestrated membrane 
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morphologies, we scored images from 1 (normal) to 5 (very severely damaged) taking 
into account membrane thickness, presence of gaps, displacement of photoreceptor cells 
into the optic lobe, as well as regularity of the basement membrane.  To obtain the mean 
score for each animal, we analyzed at least eight hemibrain sections from the same fly.  
Data from five flies per genotype were analyzed by ANOVA and Welch Two Sample t-
tests.   
Although fully viable, dbb1 and bgm1 dbb1 adults exhibit clear central nervous 
system defects, suggesting that dbb (like bgm) is required for maintenance of adult 
nervous system tissue (Fig. 2.3A-F).  We documented laminal holes in bgm1, 
bgm1/Df(bgm), dbb1 and bgm1 dbb1 18-day-old mutant flies but not in age-matched wild-
type controls (Fig. 3I), nor in newly eclosed mutants as was previously shown by Benzer.   
We observed no significant differences in the degree of degeneration of the lamina of 
age-matched bgm1 homozygotes and bgm1/Df(bgm) trans heterozygotes (p = 0.13), 
thereby genetically establishing the amorphic character of the bgm1 allele.  Statistical 
analyses revealed differences in hole numbers between single mutants and wild types to 
be highly significant (p ≤ 0.001); thus each gene is individually required for neuronal 
maintenance.  Holes were most abundant in bgm1 dbb1 double mutants (p < 0.0002 for 
comparisons both to wild types and single mutants).  Thus, these data indicate: (1) that in 
the laminal region of the brain, the bgm and dbb genes function redundantly, and (2) that 
the double mutant animal is fully penetrant and provides a more powerful resource (than 
either of the single mutants alone) for determining the effects of fatty acid dysregulation 
in neurodegeneration. 
Histological examinations of hematoxylin-eosin stained brain sections revealed 
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that in addition to laminal degeneration, which had been documented although not 
previously quantified for bgm (Min and Benzer, 1999b), both single and double mutants 
also exhibit phenotypes not previously described.  In this regard, we observed retinal 
degeneration, as well as thinning and irregularity of the fenestrated membrane—the 
structure defining the anatomic border between the retina and lamina—in bgm1, dbb1, and 
bgm1 dbb1 mutant animals.  That the aberrantly-constructed fenestrated membrane in 
ACSL mutants is functionally encumbered is most evident in double mutant animals 
where retinal nuclei can routinely be seen crossing from the retina into the lamina (Figure 
2.3G,H). In quantifying retinal and fenestrated membrane defects (Fig. 2.3J,K), we found 
that degenerative changes are stronger in the bgm1 mutant than in the dbb1 mutant (p ≤ 
0.02), although in comparisons to wild type, it was clear that dbb does contribute in 
significant fashion to retinal and fenestrated membrane structure (p = 0.015 and p = 
0.00017, respectively).  Our comparisons of retinal and fenestrated membrane 
degeneration in bgm1 and bgm1 dbb1 mutant animals did not reveal statistically significant 
differences between the two (p = 0.34 and p = 0.54), but as is true for ALD in humans, 
wide phenotypic variability was observed in double mutants, and the highest levels of 
degeneration were documented in double mutants only.  Taken together comparisons of 
wild-type and mutant retinal and laminal brain sections demonstrated that: (1) loss of the 
bgm and/or dbb-encoded ACSL results in statistically significant levels of nervous 
system impairment in all regions tested, and (2) cooperativity between the two genes 
varies by brain region - indicative of both overlapping (laminal) and cell-selective 
(retinal) outcomes for this gene pair. 
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Mutations in bgm and dbb affect lipid- and membrane-rich  
pigment cells 
To gather insight into the cellular origin of the bgm and dbb neurodegenerative 
phenotypes, we next turned to transmission electron microscopy (TEM).  We focused 
first on the fenestrated membrane, which forms the physical and electrical barrier 
between the eye and the brain.  As suggested by our initial hematoxylin-eosin-based 
analysis, we observed a substantial decrease in the extracellular component of the 
fenestrated membrane in ASCL mutants (Fig. 2.4A-D).  Ultrastructural imaging of wild-
type and mutant eyes from 18-day-old adults further revealed retinal holes, disarray in the 
normal hexagonal pattern of ommatidial structure, and perhaps most tellingly, loss of 
pigment cells (the non-neuronal support cells that surround and insulate single retinal 
ommatidial clusters) in mutants (Fig. 2.4E,F).   
The most parsimonious explanation for the fenestrated membrane defects we 
observe in ACSL mutant flies is that they arise after patterning of the Drosophila eye is 
complete.  While fenestrated membrane abnormalities have been attributed—in other 
mutant backgrounds—to defects in cell patterning during imaginal stages of Drosophila 
eye development, this class of patterning mutant reveals itself as a rough eye phenotype 
in adults, readily observed either by scanning electron microscopy or by visual 
examination (Coyle-Thompson and Banerjee, 1993).  Importantly, we have looked for the 
rough eye phenotype (by visual inspection; n>100/genotype), but have yet to observe it in 
any of our ACSL mutants.  
Next, we considered the lamina.  Although histological studies reported here and 
elsewhere (Min and Benzer, 1999b) revealed gross degenerative phenotypes in ACSL 
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mutants, our TEM studies more clearly revealed the associated cellular abnormalities.  
Particularly notable in this regard is neuronal disorganization that appears to result from 
defects in axonal path finding (Fig. 2.5A,B).  It is intriguing to speculate that this may be 
a consequence of the abnormalities in fenestrated membrane portals.  Moreover, 
inclusions like those observed in ALD pathology as well as in other human 
neurodegenerative disorders including Alzheimer’s and Parkinson’s, appear frequently in 
the lamina of bgm1 dbb1 mutant animals (Fig. 2.5C,D).  These may be a direct 
consequence of accumulating VLCFAs in mutants, as polyunsaturated VLCFAs induce 
formation of inclusions in a cell culture model of Parkinson’s disease (Assayag et al., 
2007).  Consistent with this view, but leaving the inclusions unidentified, our assays with 
the neutral lipid stains Oil Red O and Sudan Black reveal comparable patterns in wild-
type and mutant flies (data not shown).  Ultrastructural studies capture lytic cell death in 
monopolar neurons, here visualized by cell swelling and cytoplasmic clearing (Fig. 2.5E-
G; see also Fig. 2.4C,D).  Finally, accumulating granular material in the proximity of 
dying neurons points to the possibility that monopolar neuron death is due, at least in 
part, to toxic cellular inclusions (Fig. 2.5H).   
 
ACSL mutant flies recapitulate the full array of  
human ALD phenotypes 
Having established gross anatomical phenotypes in brains of bgm1, dbb1, and 
bgm1 dbb1 adults, we sought to determine whether these defects are associated with 
significant changes in fatty acid levels and/or behavioral abnormalities, features that have 
remained statistically undocumented in previous loss-of-function studies in ALD mouse 
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and fly models.  Fatty acid profiling by gas chromatography-mass spectrometry (GC-MS) 
in wild-type and ACSL single and double mutant flies revealed two statistically 
significant differences: two-fold increases of the C24:1 and C26:1 monounsaturated very 
long chain fatty acids in bgm1 dbb1 double mutant animals (Fig. 2.6A,B).  Moreover, in 
tests of locomotor activity, all mutants show an inability to match wild-type activity 
levels as evidenced by a decrease in the average number of beam breaks per animal 
within the 2-hour period before and after light change. Statistically significant differences 
in activity levels were seen within 24 hours post-eclosion and were at or near maximal 
levels by 7 days post-eclosion (Fig. 2.6C).  Like the morphological defects we 
documented above, motor defects too are reminiscent of the initial symptoms exhibited 
by ALD patients. 
When mutations in Drosophila genes are associated with neurodegeneration, 
phenotypes oftentimes extend to life span reduction (Greenspan and Dierick, 2004), and 
indeed this has been previously reported for bgm (Min and Benzer, 1999b).  In contrast to 
previous reports, we found that loss of bgm does not shorten lifespan and that loss of dbb 
only shortens life by about 10% (Fig. 2.6D).  The difference between results from our 
bgm lifespan study and those reported previously is likely attributable to differences in 
experimental protocol.  For the lifespan analyses reported here, we employed congenic 
recombinant inbred strains on an isogenic Canton S background.  Similar to our 
observations, life span changes associated with a mutation in the Drosophila gene Indy, 
coding for a Krebs cycle intermediate transporter, were abolished upon backcrossing into 
a different genetic background (Toivonen et al., 2007).  
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Mutation of the human bgm homologue Slc27a6 is  
associated with leukodystrophy 
Dysregulation of fatty acid metabolism is associated with X-ALD, but no other 
human leukodystrophies have been associated with defects in this pathway (Gordon et al., 
2014).  In the care of a child with an MRI-based diagnosis of leukodystrophy (Fig. 
2.7A,B), whole exome sequencing revealed 44 genes harboring nonsense mutations. One 
of these genes, SLC27a6, encodes a 619 amino acid dual acyl-CoA synthetase and fatty 
acid transporter, homologous to Drosophila fatp (which like bgm and dbb has ACSL 
function (supplementary material Fig. 2.2S) and has been shown to be required for 
neuronal heath and maintenance in the fly retina (Dourlen et al., 2012)).  The proband is 
heterozygous for a C>T transition that leads to production of a truncated SLC27a6 
protein 294 amino acids in length.  This allele (designated here as SLC27a6294) is very 
rare in the human population, having an overall allele frequency of 0.001% across all 
ethnicities (Exome Aggregation Consortium [ExAC]). 
Sequence analysis of the Utah affected family indicates that both the proband and 
his brother inherited the mutated Slc27a6 allele from their father and a mutated PRRT2 
allele from their mother (Fig. 7C), the latter allele being causative of an incompletely 
penetrant dominant form of epilepsy (Labate et al., 2012; Steinlein et al., 2012).  While 
the proband suffers from seizures and leukodystrophy, his brother is asymptomatic for 
both conditions (Figure 2.7B).  Comparative genotype data coupled with our observation 
that treatment of the proband with levetiracetam to control seizures stemmed the 
progression of his neurodegenerative condition leads us to speculate that in this patient, 
seizures are the neurodegenerative trigger.  There is ample evidence for other ALD cases 
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where events such as epileptic seizure or traumatic brain injury have been proposed to 
precipitate onset of leukodystrophy symptoms in previously asymptomatic patients 
(Raymond et al., 2010; Vawter-Lee et al., 2015; Weller et al., 1992). 
 
Discussion 
That mutations in lipid metabolic enzymes are associated with a variety of 
neurometabolic diseases, including Adrenoleukodystrophy, Niemann-Pick Disease, Fabry 
Disease, Farber’s Disease, Tay Sachs Disease, and Zellweger Syndrome, shows the 
nervous system to be highly sensitive to alterations in lipid homeostasis.  This sensitivity 
is thought to result from the high metabolic demand of neurons and their support cells-- a 
demand not shared by cells of other organ systems.  Investigators have identified the 
genetic basis for some of these disorders, and a number of Drosophila models have been 
described (Huang et al., 2007; Mast et al., 2011; Min and Benzer, 1999b; Nakayama et 
al., 2011; Phillips et al., 2008).   
Here we present the first fully penetrant genetic model of ALD.  Building on the 
Min and Benzer model (1999b), we have shown that the bgm1 dbb1 mutant fly exhibits 
gross neurodegenerative phenotypes in the optic lobe and retina.  We also show that 
amorphic mutations in bgm and dbb lead to VLCFA accumulation and behavioral 
abnormalities.  The consequences of the double knockout in the fly are profound, notably 
recapitulating essential features of human ALD that were not obvious in single mutants, 
thereby providing the best evidence to date of a powerful animal model of how 
dysregulation of fatty acid metabolism can lead to neurodegeneration.  In focusing on the 
similarities between fly and human phenotypes associated with VLCFA accumulation, 
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our data suggest that ALD affects both neurons and their support cells, and that excess 
fatty acid accumulation is associated with widespread cell losses in the fly brain and to 
neuronal loss via lytic cell death.  Our detection of inclusions in bgm dbb mutant flies 
augurs an attractive diagnostic tool, while the bgm dbb fly itself is expected to provide an 
effective genetic tool for identification of drugs resolving the symptoms of ALD and 
neurodegenerative disease associated with accumulating VLCFAs.  Finally, our 
identification of a leukodystrophy patient harboring a mutation in a gene with ACSL 
activity provides a basis for examination of this gene as a susceptibility factor in ALD.  
 
Neurodegeneration in ACS mutants 
Albeit viable, bgm and dbb single and double mutants suffer from optic lobe and 
retinal degeneration. That the highest levels of neurodegeneration (both with respect to 
expressivity and penetrance) are observed in double mutants points to redundant 
functions for bgm and dbb in the Drosophila CNS (see Fig. 2.3).  Functional overlap of 
bgm and dbb as long and very long chain ACSs is corroborated by elevation of very long 
chain fatty acids in the double mutant flies but not in the single mutants (see Fig. 
2.6A,B), as well as by the overlapping long chain substrate specificities documented after 
heterologous expression in yeast (see Fig. 2.1D). 
One of the most striking morphologic abnormalities in the bgm1 dbb1 double 
mutants is the loss of pigment cells (see Fig. 2.4E,F).   Pigment cell organization is 
integral to the fly retina’s lattice-like appearance, and thus loss of these cells is sufficient 
to account for the gross defects in ommatidial organization that we observe in mutants.  
Analogous disordered ommatidial phenotypes have been described in fly models of 
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Parkinson’s neurodegenerative disease and in retinal degenerative disease (Batterham et 
al., 1996; Feany and Bender, 2000; Shamloula et al., 2002).  In the case of the latter, 
retinal architectural disorder was associated with defects in pigment cells as it is also in 
our model.  Pigment cell loss is also sufficient to account for the fenestrated membrane 
dysmorphologies that we observe in mutants (see Fig 2.3H, 2.4A-D), as the fenestrated 
membrane is formed from the feet of pigment (and cone) cells.  Based on these studies, it 
appears that the effects of defective fatty acid metabolism in the fly retina are far-
reaching, affecting cell viability in both autonomous and nonautonomous fashion.  These 
observations contribute to the increasing recognition that pigments cells, and glial cells in 
general, provide critical support to the nervous system (Nave, 2010). 
We also documented disarray in laminal regions of the fly CNS, and our data 
indicate that cell loss is central to this defect as well.  Monopolar neurons in bgm1 dbb1 
brains, while maintaining an intact nuclear morphology, show signs of extensive cell 
swelling and cytoplasmic clearing (see Fig. 2.5E-G).  These ultrastructural features are 
characteristic of lytic cell death and of the pathological changes distinguishing lipid-rich 
oligodendrocyte degeneration during the initial stages of X-ALD pathogenesis (Ito et 
al., 2001; Tschape et al., 2002).  In this regard, cerebral forms of X-ALD are associated 
with progressive inflammatory demyelination of white matter that is most evident in 
parieto-ocipital regions (Moser et al., 2007). This reaction is characterized by brain 
infiltration with cytotoxic T-lymphocytes and macrophages, as well as elevation of 
inflammatory cytokines such as TNFα and interleukin I (Powers et al., 1992).  
Consistent with our characterization of monopolar neuron morphology in flies, brain 
autopsies in ALD patients reveal loss of myelin and oligodendrocyte glial cells resulting 
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from cytolytic, rather than programmed cell death (Ito et al., 2001). 
 
Accumulating VLCFAs in ACSL mutants 
A long-standing debate in the ALD field centers on the question whether 
neurodegeneration results from an accumulation of saturated or unsaturated fatty acids.  
Like others, we have shown that ACSL mutation increases VLCFA levels; in bgm dbb 
double mutants, it is C24:1 and C26:1 levels that are elevated in significant fashion (see 
Fig 2.6A,B).  This finding is consistent with our discovery that bgm and dbb have 
overlapping functions in the brain.  With respect to human disease our results 
substantiate: (1) reports of elevated unsaturated fatty acids (C24:1 and C26:1) in plasma 
and fibroblasts from X-ALD patients (Moser et al., 1999; Moser et al., 1980), and (2) 
suggestions that dietary monoene therapies such as "Lorenzo's oil" are potentially 
inefficacious in the treatment of X-ALD (Sandhir et al., 1998).  Together, these data 
contradict the commonly held view that accumulated saturated VLCFAs are causative 
of ALD.  Consistent with this idea is the observation that while all individuals harboring 
mutant alleles of ABCD1 exhibit increases in their circulating VLCFA levels, many do 
not manifest any neurodegenerative symptoms (Dubey et al., 2005; Steinberg et al., 
1993). 
At the cellular level, accumulating granular material in the proximity of dying 
neurons (see Fig 2.5F-H) points to the possibility that monopolar neuron death is due, at 
least in part, to toxicity of accumulated metabolic byproducts, even though Nile red and 
Sudan black stains suggest it is unlikely that bgm dbb laminal inclusions themselves 
represent fatty acid accumulations.  Bolstering this view are published studies 
 62 
including: (1) the suggestion that excess fatty acids are causative of cell death in both 
Leydig and adrenocortical cells in X-ALD patients (Powers and Schaumburg, 1981); (2) 
evidence in cultured cells that free VLCFAs induce apoptosis by activation of the pro-
inflammatory TNF-mediated pathway and by formation of free radicals that induce 
mitochondrial damage (Feigenbaum et al., 2000; Reiser et al., 2006; Ulloth et al., 2003); 
and (3) the demonstration in cultured rat hippocampal cells that VLCFA challenge 
specifically promotes their death (Hein et al., 2008).  In in vivo models, however, while 
metabolic abnormalities are causative of cell death, accumulated lipids serve primarily 
as markers of neurodegeneration (Liu et al., 2015).   
At the very least, presence of fatty acid inclusions in brain tissue and the elevated 
levels of VLCFAs in bgm dbb mutant flies suggest a link between observed 
neuropathology and fatty acid accumulation.  It should be noted that both saturated and 
monounsaturated VLCFAs accumulate in both plasma and fibroblasts of X-ALD patients 
and Zellweger patients (Powers and Moser, 1998; Sandhir et al., 1998).  Similar to 
saturated free fatty acids, monoenolic free fatty acids show toxicity in tissue cultures 
causing both apoptotic and necrotic cell death (Andrade et al., 2005; Martins de Lima et 
al., 2006).  Importantly, direct toxicity of unsaturated fatty acids was observed in 
neonatal ALD cells (Bachir Bioukar et al., 1994).  Based on these observations, we 
propose that the Drosophila bgm dbb mutant serves as a powerful in vivo model linking 
fatty acid accumulation to neurodegeneration.  Moreover, our data suggest that the 
mechanisms of neuronal cell damage observed in Drosophila bgm dbb mutants are 
similar to those associated with the first stage of X-ALD pathogenesis.  The primary 
assault on CNS cells in X-ALD patients is believed to result from impaired homeostasis 
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of very long-chain fatty acids that leads to membrane instability, cell lysis and eventually 
to fulminant inflammatory response (Powers et al., 2005). 
 
Drosophila models of neurodegeneration 
The Drosophila bgm dbb mutant represents a significant addition to a growing 
family of fly models of neurometabolic disease.   Within this group, the 
neurodegenerative diseases have a variety of associated abnormalities.  One of the best 
characterized in Drosophila is swiss cheese (sws) (Muhlig-Versen et al., 2005).  sws 
mutants suffer from a bgm dbb-like age dependent neurodegeneration, although holes 
develop more rapidly, more prominently, and across a wider expanse of the CNS than 
occurs in bgm and dbb mutants, and although the retina is notably spared.  sws codes for 
an esterase, which when disrupted in humans leads to the neurodegenerative condition 
spastic paraplegia (Rainier et al., 2008).  This esterase is required for hydrolyzing 
phosphatidylcholine, and loss-of-function mutations in either humans or flies results in an 
abnormal buildup of phosphatidylcholine (Fernandez-Murray and McMaster, 2007; 
Glynn, 2005; Muhlig-Versen et al., 2005).  Thus, the etiology of degeneration for 
neuropathy target esterase-mediated neurodegeneration is very likely analogous to that 
which is proposed for Adrenoleukodystrophy-- blockage in a metabolic pathway leading 
to an abnormal accumulation of toxic lipids (Read et al., 2009).  
More recent descriptions of Drosophila neurodegeneration mutants reveal those 
with age-dependent neurodegenerative phenotypes that like bgm and dbb target the retina.  
Intriguingly two of these (dPPCS and fumble/dpank) function in the CoA synthetic 
pathway (Bosveld et al., 2008; Siudeja et al., 2011).  The Drosophila model of 
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neurometabolic disease most analogous to our bgm/dbb model is the fatp mutant.  
Animals harboring retinal clones homozygous for the null allele, fatpk10307, manifest an 
age-dependent neurodegeneration that is characterized by disorganization of the retina 
and significant pigment cell loss (Dourlen et al., 2012).  Taken together, the shared loss-
of-function phenotypes associated with mutation of long- and very long chain-ACSs in 
Drosophila (bgm, dbb, and fatp) suggest that these genes, and the lipid metabolic 
pathway(s) in which they act, play an essential role in neuromaintenance, and that in the 
case of Fatp (as it is for Bgm and Dbb) it is the synthetase function that is necessary for 
CNS health and maintenance.  Moreover, in light of the specific and striking shared loss-
of-function bgm, dbb, and fatp phenotypes in flies, it is significant that our patient study 
reveals an association of fatp/SLC27a6 loss-of-function with leukodystrophy in humans.     
 
 
Association of a human ACSL with leukodystrophy 
Our identification of the first leukodystrophy patient to harbor a nonsense 
mutation in SLC27a6, a gene encoding a predicted dual functioning ACSL and fatty 
acid transporter, is particularly compelling, as it suggests that mutations in the ACSL 
family of genes can be causative of neurodegeneration in humans as they are in flies.  
Indeed it has long been thought that ACSL mutations might be associated with ALD as 
ACSL levels are decreased in ALD patients (Hashmi et al., 1986; Lazo et al., 1988; 
Wanders et al., 1988b).  The mode of inheritance of SLC27a6294-associated 
neurodegenerative disease appears to be autosomal dominant, as is the case for several 
well-documented neurodegenerative conditions in humans (Bertram and Tanzi, 2005).  
The nonsense mutation that we document in our leukodystrophy patient is quite rare 
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(allele frequency: 0.001335), albeit more common than any of the other 41 predicted 
loss-of-function alleles in the ExAC database (allele frequency: 0.00007120) with the 
exception of one (allele frequency: 0.0022) (Exome Aggregation Consortium, 2015).  
The two most common alleles are almost certainly nulls: one with premature 
termination after AA 294; the other with a frameshift after AA 8.  It is likely they each 
arose only once in isolated populations as each clusters in a single ethnic population 
database.  We expect that homozygosity for loss-of-function SLC27a6 alleles results in 
a highly penetrant zygotic lethality as only one loss-of-function homozygote (for any 
allele) has been identified to date.   The scarcity of mutant alleles in the human 
population, coupled with a paucity of diagnostic sequence data in affected individuals 
and an incompletely penetrant phenotype provides an explanation for our failure until 
now to associate SLC27a6 with leukodystrophy.  Thus, like fly bgm and dbb, and 
human ABCD1, Slc27a6 is likely causative of an incompletely penetrant 
neurodegenerative phenotype, albeit in dominant fashion. 
 
Summary 
The bgm dbb double mutant animal has provided unique insights into the 
organismal (locomotor activity), tissue (neurodegeneration), and cellular (monopolar 
neuron and pigment cell death) requirements for long and very long chain fatty acids.  
Central nervous system degeneration that is associated with behavioral and biochemical 
abnormalities in both flies and humans underscores the power of our model for 
continuing to probe disease etiology as well as to initiate investigation of palliative 
treatment options.  Moreover, in addition to revealing severe neurological involvement, 
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activity phenotypes can be monitored in higher throughput assays, and this opportunity 
underscores the feasibility of suppression screens for the identification of compounds 
and/or dietary regimens that alleviate the abnormalities associated with ACS mutation.  
Finally, highlighting the continuing power of simple invertebrate genetic models, this 
basic science study has led to our recognition of a new candidate susceptibility gene for 
catastrophic presentation of leukodystrophy (Vawter-Lee et al., 2015).    
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Figure 2.1 bgm and dbb are duplicated genes that encode bona fide acyl-CoA 
synthetases.  (A) Enzymology of VLCFA degradation in peroxisomes.  When transport 
to the peroxisome is blocked by mutation of either the synthetase (ACSL) or the 
transporter (ABCD1), which is shown here as a dimer (oval pair) resident in the 
peroxisomal membrane, VLCFAs accumulate intracellularly (gray arrow).  (B) A 
phylogenetic tree of the eight acyl-CoA synthetases in D. melanogaster.  (C) 
Organization of the bubblegum and double bubble genes on Drosophila chromosome 2.  
(D) Cerulenin renders yeast auxotrophic and dependent on imported fatty acids and the 
activity of FAA1.  Both bgm and dbb restore growth to FAA1-deficient yeast when 
myristate is added to the growth medium.  Only bgm complements FAA-1 in the presence 






















































Figure 2.2 Generation of dbb and bgm dbb mutant animals.  (A) Schema showing the 
ends-out gene targeting strategy employed for generation of dbb single and bgm dbb 
double mutant animals, as well as positions of primers used for analytical PCR.  (B) 
Verification of the putative dbb1 and bgm1 dbb1 alleles by PCR.  M denotes the marker 
lane and includes bands corresponding to 10, 8, 6 and 5 kb lengths.  (C) Verification of 




















































Figure 2.3 Degeneration of the CNS in Acyl-CoA synthetase mutants.  (A) Labeled 
schematization of a Drosophila brain horizontal section.  (B-F) Hematoxylin-eosin 
stained brain sections representative of wild-type, bgm1, bgm1/ Df(2L)b87e25, dbb1, and 
bgm1 dbb1 animals, respectively.  In C-F retinal degeneration is marked by black arrows 
and laminal degeneration by white arrows.  (G) Labeled schematization of a horizontal 
section of the Drosophila retina.  (H) Magnified fenestrated membranes from animals 
shown in B-E.  Note enlarged portals (dashed boxes, containing in the case of the bgm 
dbb double mutant displaced retinal nuclei).  Degeneration in (I) lamina and (J) retina, 
as well as (K) defects in the fenestrated basement membrane, were quantified.  For 
these plots, data obtained from analysis of hematoxylin-eosin brain sections were 
analyzed by ANOVA and by the Welch Two Sample t-Test.  Each point represents the 
mean score per animal; horizontal lines represent the mean score per genotype.  
Statistical significance determined by ANOVA followed by student’s t-test: *** p < 























































































































Figure 2.4 Neuronal death and pigment cell defects in Acyl-CoA synthetase mutants.  
Ultrastructural analysis of heads from 18-day-old (A) wild-type, (B) dbb1, (C) bgm1, and 
(D) bgm1 dbb1 flies. A thinned fenestrated membrane is evident in comparisons of wild-
type and mutant animals (boxed in panels A-D). Also, lytic death of monopolar neurons
is evident in the lamina of mutant, but not wild-type animals.  In A-D, monopolar
neurons are indicated by arrows while R denotes the retinal domain and L denotes the
laminal domain.  Ultrastructural analysis of retinas from 18-day-old (E) wild-type and (F)
bgm1 dbb1 flies. Loss of the ommatidial structure (outlined) in the bgm dbb double
mutant retina is correlated with loss of secondary pigment cells; these surround each
ommatidial cluster of photoreceptor neurons and in these images appear as empty white























Figure 2.5 Neurodegeneration is associated with laminal deposits in bgm dbb double 
mutants.  Ultrastructural analyses of lamina in (A) wild-type, (B) dbb1 and (C) bgm1 
mutant animals reveal the lamina of mutants to be highly disorganized. Note the parallel 
oragnization of photoreceptor axons in wild-type brains, and their misorientation in dbb 
mutants (outlined in black in A and B).  These structures are absent from bgm mutants in 
which densely stained inclusions are abundant (e.g., boxed region in C).  (D) The boxed 
region from panel C was imaged at higher magnification.  (E) In wild-type animals, 
monopolar neurons (outlined in white) are distinguished by their nucleolar content.  In 
mutants (F,G), however, monopolar neurons are distinguished by cytoplasmic swelling 
and lytic cell death.  Lysing monopolar neurons are oftentimes found in association with 
extracellular precipitates (arrow in F and boxed in G).  (H) The precipitate from panel G 
was imaged at higher magnification, revealing it to be granular and thus structurally 
identical to previously described fatty acid precipitates.  
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Figure 2.6. bgm dbb mutants recapitulate Adrenoleukodystrophy phenotypes.  Gas 
chromatography mass spectrometry analysis (A) C24:1 and (B) C26:1 in bgm dbb mutant 
heads; *p = 0.04.  (C) Locomotor activity in wild-type and mutant flies; Student’s t-Test, 
with standard errors of the mean shown; *p < 0.05, **p < 0.01, ***p < 0.001.  (C) 
Kaplan-Meir survival estimates for wild-type and mutant flies (n≥150/genotype).  
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Figure 2.7  Identification of a leukodystrophy patient harboring a mutation in 
SLC27a6.  (A) MRI scan of an 18-month-old boy presenting with epilepsy.  Arrow head 
points to one of the expanded lateral ventricles, diagnostic of leukodystrophy; the paired 
structural defect is evident on the right side as well. (B) Pedigree shows family member 
phenotypes: PRRT2-dependent benign familial infantile epilepsy (vertical hatching); 
leukodystrophy (horizontal hatching). The proband is designated as #1038.  (C) Sequence 
data for SLC27a6 and PRRT2, respectively.  Carriers of the SLC27a6 mutant allele have a 
C>T transition; the resultant nonsense mutation leads to premature termination of the
protein.  Carriers of the PRRT2 mutant allele have a C duplication at position 649; this
frameshift leads to premature termination of the protein.
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Figure 2.S1. Basic local alignment of the Drosophila bgm and dbb genes with their 
human (ACSBG1 and ACSBG2) and mouse (Acsbg1 and Acsbg2) homologues. 
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Figure 2.S2. COBALT alignment of human SLC27a6, and Drosophila Fatp, Bgm, and 
Dbb.  Dark and light blue bars above the protein sequences delimit the two functionally 
conserved ACS sites: the 10 amino acid AMP binding domain and the 35 amino acid 
substrate specificity domain, respectively.  The red asterisk demarcates the site of 
premature termination in the SLC27a6294 variant. 
10001  1    MLLSWLTVLGAGMVVLHFLQKLLFPYFWDDFWFV-------LKVVLIIIRLKKYEKRGELV---TVLDKFLSHAKRQPRK  70 
10002  1   --MGWIFAVLVALVAL-----LLTKPGWRWFYIAGATASRDLTALWAYIKLLRYTKRHERL-NYTVADVFERNVQAHPDK  72 
10003  1   ---------------MSTIDALYNRPGPNRLRQADAYRTTNRQDA-VKIRMAKDGIGAEE--PISVPGLLKRTVNNYGDY  62 
10004  1   ---------------M------------NDLKPATSYRSTSLHDA-VKLRLDEPSSFSQTVpPQTIPEFFKESCEKYSDL  52 
10001  71   PFIIYEG-----DIY---TYQDVDKRSSRVAHVFLNhSSLKKGDTVALLMSNEPDFVHVWFGLAKLGCVVAFLNTNIRSN  142 
10002  73   VAVVSET-----QRW---TFRQVNEHANKVANVLQA-QGYKKGDVVALLLENRAEYVATWLGLSKIGVITPLINTNLRGP  143 
10003  63   PALRTK---NGKNGYHTVTYKQYEQKVHQVAKAFIK-LGLEEHHSVGVLAFNCAEWFYSAMGAIHARGIIAGIYTTNSAD  138 
10004  53   PALVWETpgSGNDGWTTLTFGEYQERVEQAALMLLS-VGVEERSSVGILAFNCPEWFFAEFGALRAGAVVAGVYPSNSAE  131 
10001  143  SLLNCIRACGPRALVVGADL-LGTVEEILPSLSENISVWGMKD---------------SVPQGV---ISLKEKLSTSPDE  203 
10002  144  SLLHSITVAHCSALIYGEDF-LEAVTDVAKDLPANLTLFQFNN------ENNNSETEKNIPQAKNLNALLTTASYEKPNK  216 
10003  139  AVQHVLESSHAQIVVVDDAKQMDKIHAIRDKLPKLKAAIQIQEPYSPYLKKEDGYYRWSEIESMNVS-DVEDQYMTRLEN  217 
10004  132  AVHHVLATGESSVCVVDDAQQMAKLRAIKERLPRLKAVIQLHGPFEAFVDHEPGYFSWQKLQEQTFSSELKEELLARESR  211 
10001  204  PVPR[7]LKSTCLYIFTSGTTGLPKAAVISQLQVLRGSAVLWAFGCT----AHDIVYIT-LPLYHSSAAILGISGCVELG  282 
10002  217  TQVN   HHDKLVYIYTSGTTGLPKAAVISHSRYLFIAAGIHYTMGF----QEEDIFYTpLPLYHTAGGIMCMGQSVLFG  289 
10003  218  VAIN  --ECCCLVYTSGTVGMPKGVMLSHDNITFDVRGIVKAMDRVVVGAESIVSYL--PLSHVAAQTVDIYTCAFVA  290 
10004  212  IRAN  --ECAMLIFTSGTVGMPKAVMLSHDNLVFDTKSAAAHMQDIQVGKESFVSYL--PLSHVAAQIFDVFLGLSHA  284 
10001  283  ATCVLKKKFS-ASQFWSDCKKYDVTVFQYIGELCRYLCKQSKREGEKDHKVRLAIGNGIRSDVWREFL------------  349 
10002  290  STVSIRKKFS-ASNYFADCAKYNATIGQYIGEMARYILATKPSEYDQKHRVRLVFGNGLRPQIWPQFV------------  356 
10003  291  GCIWFADKDALKGTLVKSLQDARPTRFMGVPRVYEKFQERMVAVASSSGSLKKMLASWAKGITLKHYM-VSQGKSS---G  366 
10004  285  GCVTFADKDALKGTLIKTFRKARPTKMFGVPRVFEKLQERLVAAEAKARPYSRLLLARARAAVAEHQTtLMAGKSPsiyG  364 
10001  350 -DRFGNI----------------------------------------KVCELYAATESSISFMNYTGRIGAIGRTNLFYK  388
10002  357 -QRFNIA----------------------------------------KVGEFYGATEGNANIMNHDNTVGAIGFVSRILP  395
10003  367  GFRYKIAkSLIMSKVKQALGFDRVLTLASAAAPMSPETKKYFLSLDLKIVDAFGMSETAGCH------------TICLPD  434 
10004  365  NAKYWLA-CRVVKPIREMIGVDNCRVFFTGGAPTSEELKQFFLGLDIALGECYGMSETSGAI------------TLNVDI  431 
10001  389  LLSTFDLIKYDFQKDEPMRNEQGWCIHVKKGEPGLLISRVNAKNP---FFGYAGPYKHTKDKLLCDVFKKGDVYLNTGDL  465 
10002  396  KIYPISIIRADPDTGEPIRDRNGLCQLCAPNEPGVFIGKIVKGNPSREFLGYVDE-KASAKKIVKDVFKHGDMAFISGDL  474 
10003  435  SVGLNTIGKTLPGCESKFINKDA-------NGHGELCIR-----GRHVFMGYIDNKEKTEESLDDDCW------LHSGDL  496 
10004  432  S-NLYSAGQACEGVTLKIHEPDC-------NGQGEILMR-----GRLVFMGYLGLPDKTEETVKEDGW------LHSGDL  492
10001  466  IVQDQDNFLYFWDRTGDTFRWK-GENVATTEVADVIG-MLDFIQEANVYG-------VAIS---GYEGRAGMASIILKPN  533 
10002  475  LVADEKGYLYFKDRTGDTFRWK-GENVSTSEVEAQVS-NVAGYKDTVVYG-------VTIP---HTEGRAGMAAIY-DPE  541 
10003  497  GFVDDKGYVSLTGRSKEIIITAGGENIPPVHIENTIKKELDAISNAFLVGEQRKYLTVLITLKTEVDKDSGEPLDELSHE  576 
10004  493  GYIDPKGNLIISGRLKELIITAGGENIPPVHIEELIKKELPCVSNVLLIGDHRKYLTVLLSLKTKCDAKTGIPLDALREE  572 
10001  534  TSL---DLEKVYEQVVTFL   PAYAC   PRFLRIQE-------KMEATGTFKLLKHQLVEDGFN--PLKISEPLYFM  594 
10002  542  REL---DLDVFAASLAKVL   PAYAR   PQIIRLLT-------KVDLTGTFKLRKVDLQKEGYD--PNAIKDALYYQ  602 
10003  577  SSVWVKSLGVEHKTVSDIL   AAGPC   PKVWKSIEDAIKRANKQSISNAQKVQKFTILPHDFSIPTGELGPTLKVK  649 
10004  573  TIEWLRDLDIHETRLSELL[12]AALAA[7]PKLLEAIEEGIKRANKYAISNAQKVQKFALIAHEFSVATGELGPTLKIR  664 
10001  595  DNL-KKSYVLLTRELYDQIMLGEIKL  619 
10002  603  TS--KGRYELLTPQVYDQVQRNEIRF  626 
10003  650  RNVVSKMYADEIEKLYA---------  666 















































REVIVAL OF DIETARY THERAPY IN A DROSOPHILA  
MODEL OF ALD SUPPORTS A REQUIREMENT  
OF ACSL FATTY ACID PRODUCT 
 
Introduction 
As the average age increases, so too does the risk of developing 
neurodegenerative disease (Hung et al., 2010).  Yet, while patient populations continue to 
grow, the etiology of these diseases remains poorly understood, due in part to the diverse 
and complex nature of the molecular mechanisms surrounding neurodegeneration.  
Leukodystrophies represent one class of degenerative diseases that affect the white matter 
of the brain and have a broad range for age of onset with varying life expectancies 
(Gordon et al., 2014).  It is estimated that a little over half of the individuals who present 
with the serious clinical symptom of abnormal white matter in MRI scans do not resolve 
to a clear causal diagnosis, exemplifying the need to understand the molecular nature of 
such severe defects (Bonkowsky et al., 2010; van der Knaap et al., 1999).  Of the more 
commonly diagnosed forms of this is degenerative disease is Adrenoleukodystrophy 
(ALD).    
At the cellular level, the only form of ALD with a defined genetic cause, results 
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from mutation of ABCD1 (Moser et al., 1992). ABCD1 is a peroxisomal protein required 
for import of very long chain fatty acids (VLCFAs) into the lumen of the peroxisome 
where initial steps of b-oxidation occur.  Thus, ALD disease etiology appears to be rooted 
in irregularities in lipid homeostasis.  In this regard, ALD is not unique as many other 
neurodegenerative diseases are also caused by variants in genes whose proteins play key 
roles in lipid metabolism (acid sphingomyelinase: Niemen Pick type A OMIM#257200, 
alpha-galatosidase A deficiency: Fabry disease OMIM#301500, and acid ceramidase: 
Farber’s disease OMIM#228000).  
The clinical heterogeneity displayed with inheritance of the same null allele of 
ABCD1 has led many to speculate genetic and/or environmental modifiers must play a 
role in ALD presentation.  Acyl CoA synthetases represent the first, and initially favored 
enzyme linking the accumulation of VLCFA metabolism to ALD pathology (Lazo et al., 
1988; Wanders et al., 1988). Early observations noted a biochemical defect in activation 
of the long and very long chain family of fatty acids in tissues of affected patients 
(Hashmi et al., 1986).  Indeed, evidence has emerged that ABCD1 and multiple cellular 
ACSs physically interact and in some cases, this interaction is required for proper protein 
function.  Yeast two-hybrid studies identify a physical interaction between mouse 
ABCD1 and a very long chain ACS (ACSVL1/SLC27a2) (Makkar et al., 2006).  Co-
immunoprecipitation studies as well as BRET (bioluminescence resonance energy 
transfer) assays identify ABCD1 and ACSVL5 (SLC27a1) as binding partners 
(Hillebrand et al., 2012). Finally, expression studies utilizing murine fibroblasts deficient 
for ABCD1 revealed that ACS activity is dependent on ABCD1 protein levels.  This may 
be due to a requirement for ABCD1 to tether ACS to the peroxisomal membrane as 
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ACSVL1 localizes to the peroxisomal membrane (Lageweg et al., 1991; Lazo et al., 
1988).  Previous reports from our lab and others have documented a neurodegenerative 
phenotype in Drosophila that are homozygous for null alleles for the ACSVLs bgm and 
dbb (Sivachenko and Gordon et al., 2015, submitted/Chapter 2; (Min and Benzer, 1999).  
Both single and double mutants display age-dependent central nervous system 
degeneration in the optic lobe, thereby providing the most clinically relevant animal 
model of ALD to-date.  
An increase in VLCFAs in circulating plasma and affected tissues is a key 
diagnostic feature of ALD (Igarashi et al., 1976), and most current models of ALD 
envision neurodegeneration to result from a toxic accumulation of VLCFAs within tissue 
leading to cell death (Berger et al., 2010).  However, at least three lines of evidence do 
not align with this idea.  First, 20% of individuals with null ABCD1 mutations exhibit an 
increase in VLCFAs without any nervous system involvement (Raymond et al., 2010; 
Steinberg et al., 1993; Weller et al., 1992).  That these individuals do not manifest 
neurodegenerative phenotypes despite an equivalent accumulation of VLCFA seen in 
affected individuals suggests that an accumulation itself is not sufficient for 
neurodegeneration.  Additionally, VLCFA concentrations do not correlate with the 
degree of neurological disability (Moser, 1997). Second, multiple groups have 
independently generated ABCD1 knockout mouse models.  In all three reports, animals 
exhibit increased VLCFAs in multiple tissues and plasma (including the CNS and adrenal 
glands) yet do not show central nervous system phenotypes that resemble ALD (Forss-
Petter et al., 1997; Fourcade et al., 2009; Kobayashi et al., 1997; Lu et al., 1997; Yamada 
et al., 2000).  Moreover, examination of cellular morphology in ABCD1 mutants 
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uncovered a swollen morphology and lipid-like inclusions in the adrenal cortex, testis, 
and ovaries, suggesting that mutant animals do in fact suffer from a VLCFA storage 
disorder albeit without CNS impairment (Forss-Petter et al., 1997).  In one model, aged 
(15 months) animals display an incompletely penetrant AMN-like phenotype in the 
peripheral nervous system (Pujol et al., 2002), used animals from Lu et al., 1997). Third, 
hematopoetic stem cell transplants in ALD patients have shown promise in halting 
neurodegeneration despite plasma VLCFA concentrations remaining high (Cartier et al., 
2009).  Taken together, these data suggest that VLCFA concentrations in ALD, while 
representing an important biomarker, are not causative of neurodegeneration.   
In light of these data, the relevance of an increase in VLCFAs in X-ALD patients 
and in the bgm dbb Drosophila model of ALD represents a persistent question in the 
etiology of ALD.  Another significant question in the ALD field focuses on the tissue 
specific requirements of ABCD1 and ACSL metabolism.  At the tissue level, ALD and 
other leukodystrophies affect brain white matter that contains neurons as well as glia, and 
often a robust immune response (Powers et al., 1992).  It is so far unknown whether all 
three of these tissue types represent cells with a primary defect due to the absence of 
ABCD1 or whether only some represent the primary cell type affected while other cell 
types represent secondary effects triggered by the initial cell death and dysfunction.  
Determining between these two models of tissue incorporation in degeneration is 
important for correct targeting of therapies for ALD.  Functional tissue specific 
requirements of ABCD1 or other members of the ACSL pathway have been thwarted due 
in part to the lack of these tools in other models, and additionally, due to a lack of a clear 
central nervous system phenotype in multiple mouse models of ALD (Berger and 
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Gartner, 2006; Forss-Petter et al., 1997; Kobayashi et al., 1997; Lu et al., 1997; Pujol et 
al., 2002).  We have shown that in the Drosophila ALD model, neurodegeneration in the 
CNS is profound, affecting both neurons and their support cells (Sivachenko and Gordon 
et al., 2015, submitted/Chapter 2) in agreement with gross tissue disruption in ALD 
patients (Kemp et al., 2012).  Therefore, our fly model, as the only standing ALD model 
with central nervous system degeneration, can be uniquely used to address this question.    
Building on previous reports from our lab documenting the neurodegenerative 
phenotype in aged bgm and dbb mutant animals we answered these long-standing 
questions surrounding the etiology of ALD.  Here we dissect the bgm and dbb animals at 
the cellular and molecular levels by determining the tissue specificity of the ACSL 
pathway as well as the cellular defects leading to death and degeneration.  These findings 
provide a basis for novel therapeutic approaches and strongly suggest a new proposed 
mechanism of neurodegenerative progression in ALD. 
 
Materials and Methods 
Drosophila stocks 
Flies were raised on standard cornmeal diet at 25oC, with 12-hour light:dark 
cycles unless otherwise noted.  The following strains were obtained from the 
Bloomington Drosophila Stock Center and used to drive UAS expression: repo-Gal4 
(BL#7415), elav-Gal4 (BL#8690), sim-Gal4 (BL#9150), DJ667-Gal4 (BL#8171).  
tubulin-Gal4 (w1118; P{tubP-gal4}LL7}/TM3, P{Dfd-GMR-nvYFP}3 Sb1) was gifted 
by the Metzstein Lab (Utah).  bgm1 was gifted by Seymour Benzer.  dbb1 animals were 
generated as previously described (Sivachenko et al., 2015, chapter 2).  RNAi lines 
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targeting CG2316 and CG2781 are from the Transgenic RNAi Project at Harvard 
Medical School (stocks 41984 and 50710, respectively).  
Medium chain diets were prepared as previously described (Birse et al., 2010).  
Long chain diet was prepared as previously described (Carvalho et al., 2012). Adult 
males were collected within 24 hours of eclosion and maintained on all diets from within 
one day of eclosion to 20-22 days post-eclosion when heads were isolated and samples 
were blinded for plastic sectioning. 
For light manipulations, males were isolated within 48 hours of eclosion and 
exposed to: 24 hours light, 12 hours light/dark, or 24 hours of darkness in a temperature 
and humidity-controlled room.  
 
Ageing and histology 
Adult Drosophila males were prepared by rinsing heads in MeOH and removing 
mouthparts and air sacs before fixation in 4% formaldehyde/PBS for 30 minutes at RT.  
Heads were dehydrated through serial MeOH/H2O washes before transferring to 1:1 
MeOH:Solution A, and then equilibrated in solely Solution A at 4oC overnight (100 ml 
Solution A:1gram catalyst, Electron Microscopy Sciences Immuno-Bed Infiltrate cat. no. 
14260-01, 14260-06, respectively).  Embedding was performed by mixing 1:20 Solutions 
B:A (Solution B, Electron Microscopy Sciences cat no 14260-04) and orienting heads in 
chuck molds for saggital sections. Plastic blocks were sectioned at 8uM thickness and 
stained with 0.1% Toluidine Blue to increase photoreceptor contrast.  All samples were 
imaged at 600x using a Zeiss Axioskop 50 and Axiovision4 camera software. 
 
	   97	  
Phenotype analysis and neurodegeneration scores 
Three to five serial sections for each animal were blindly scored on a scale from 
0-3 for qualitative disruptions in the retinal pattern where 0=no abnormalities/unaffected, 
1=less affected, 2=affected, 3=strongly affected (Cao et al., 2013). Scores for each animal 
were then averaged within each genotype and standard error was graphed.  
 
Transgenic generation and genetics 
The coding sequence of bgm was subcloned into a pUAST vector using the 
following primers 5’-ATAAAGCTTATGTCCACGATAGACGCGCTC-3’ and 5’-
GCGGTACCGGCATATAGTTTCTCGATCTC-3’. UAS-bgm-FLAG plasmid was 
sequence verified then injected into dechorionated embryos with the attB plasmid 
containing the UAS-bgm-FLAG construct into the posterior end of nosΦC31;+;vk27 
embryos 1-2 hours after egg lay. All surviving progeny were screened by crossing to 
w;Dr/TM3Sb for detection of germline transmission (G0 founders). Siblings of G0 
founders were crossed and homozygous stocks were amplified and maintained under 
standard conditions.  Once we generated a transgenic stock containing a single copy of 
UAS-bgm in the attP site, we next established independent lines with animals 
homozygous for bgm on the second chromosome and containing either 1) the UAS-bgm-
FLAG transgene or 2) various tissue-specific GAL4 drivers (reversed polarity, single 
minded, DJ667, and tubulin).  Progeny of crossing the UAS-bgm-FLAG line with lines 
containing each driver were collected within 24 hours of eclosion and aged. 
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Statistical analysis 
Data were analyzed using GraphPad Prism software (GraphPad Software). In all 
tests, P < 0.05 was considered significant.  
 
Results 
Early onset of neurodegenerative disease in ACSL mutant flies 
With the long-term goal of developing a more rapid and sensitive means to assess 
neurodegenerative phenotypes, we turned to plastic sectioning of transverse cross 
sections observed under light microscopy.  The fly eye comprises ~800 ommatidia 
arranged in a highly organized rosette orientation. This regular arrangement allows us to 
detect even subtle disturbances of cell structure as well as finer resolution for which cell 
types are disturbed in mutant animals.  While wild-type animals maintain a well 
organized retinal pattern through at least 20 days of adulthood, bgm and dbb mutant 
animals show a dramatic neurodegenerative phenotype (Fig. 3.1A-C).  Disruption in the 
retinal pattern in bgm and dbb mutants was primarily due to missing glial-like pigment 
cells, and we rarely saw missing photoreceptors.  The defects were completely penetrant 
in 20-day-old bgm animals, but incompletely penetrant in age-matched dbb mutants.  
Using this assay, we were able for the first time to identify retinal defects in both mutants 
as early as 5 days post-eclosion, although defects in the younger flies were more subtle in 
most animals (Fig. 3.1D-F, J).  In agreement with earlier reports (Sivachenko and 
Gordon et al., 2015, Chapter 2; (Min and Benzer, 1999), we see no abnormalities in either 
wild-type or mutant animals at day 0 post-eclosion (Fig. 3.1G-I,J).  Thus, we conclude 
that transverse cross sections in our system allowed sensitive detection of 
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neurodegeneration that can be utilized for high-throughput analysis.  Defects are 
detectable as early as day 5 days post eclosion, and are fully penetrant at 20 days post-
eclosion (Fig. 3.1 J).  
 
The ACS/ABCD1 FA metabolic pathway functions in  
neurons to affect central nervous system health 
To determine if Bgm function is required in neurons or glia for preventing 
degeneration, we utilized the UAS/GAL4 bipartite system (Brand and Perrimon, 1993) to 
express Bgm in neuronal or glial cells in bgm mutants.  First, we tested whether 
ubiquitous expression of bgm rescued the defects in neuromaintenance of the retinal 
pattern that we see at day 20 by expressing the bgm transgene under the tubulin driver 
(Fig. 3.2 B).  We conclude that the bgm transgene is functional, as we see full rescue at 
day 20, where we otherwise observed complete penetrance defects in maintaining retinal 
structure (Fig. 3.1 B).  Next, we tested a tissue-specific requirement of bgm in 
neuromaintenance. To do this, we used glial (repo) and neuronal (sim) drivers, 
corresponding to the two tissues in which we see defects in retinal structure in bgm and 
dbb mutants.  Surprisingly, despite bgm mutants showing primarily glial defects, glial-
specific bgm expression was not sufficient to rescue neuromaintenance: neural specific 
expression, however, was sufficient for rescue (Fig. 3.2C,D).  These data indicate bgm is 
required in neurons but not in glia for maintenance of retinal structure.  Finally, 
expression of bgm primarily in muscles failed to rescue, showing specificity of 
expression to the retina is required for rescue (Fig. 3.2E).   
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Other ACSL pathway members are required  
for neuromaintenance 
The neuron-specific requirements for bgm in Drosophila suggest that other ACSL 
pathway members implicated in ALD are also neuron specific.  To test this hypothesis, 
we tested whether ABCD1—the only known gene to be causative of ALD in humans—
has a neuron-specific requirement in Drosophila.  Importantly, the requirement for the 
Drosophila homolog of human ABCD1 has never been tested (no genetic mutants).  
Through reciprocal BLASTp searches, we identified CG2316 as the most closely related 
Drosophila gene to human ABCD1.  This gene, which we will refer to as dABCD1 is 53% 
identical and 71% similar to human ABCD1.  Expression data from both FlyAtlas 
(Chintapalli et al., 2007) and modENCODE (Celniker et al., 2009) confirm moderate to 
high levels of dABCD1 transcript expression in the adult head, correlating with a 
potential requirement of this gene in adult neuromaintenance (Flybase).  dABCD1 resides 
on the fourth chromosome and no loss of function mutations of ABCD1 has been 
described.  Thus, we employed RNAi to target the dABCD1 transcript in a tissue-specific 
manner to test which tissues require dABCD1 and whether the defects are similar to those 
caused by bgm loss of function.  As is the case for genetic nulls of bgm and dbb, flies 
survive ubiquitous disruption of dABCD1 (Fig. 3.3 A-C). dABCD1 tub>RNAi adults exhibit a 
striking shared loss-of-function defects with bgm and dbb, including retinal holes and 
disrupted pigment cells upon aging (Fig. 3.3A-C).  Targeted disruption of dABCD1 
mRNA in neuronal cells using either the sim or elav drivers resulted in retinal pattern 
defects indistinguishable from bgm mutant animals (Fig. 3.3 D,E).  Glial expression 
driven under repo-GAL4 has no effect (Fig. 3.3 F).  Thus, we conclude that dABCD1—
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similar to bgm and dbb—are required in neuronal cells for correct retinal structure.  With 
shared loss of function defects seen with three components of the ACSL pathway (bgm, 
dbb, dABCD1), we sought to establish the cellular mechanism of neurodegeneration in 
these animals.  
 
ACSL enzyme fatty acid product is required  
for neuromaintenance 
One key diagnostic feature in ALD patients is increased levels of the VLCFAs 
C24 and C26 in circulating plasma (Igarashi et al., 1976).  These accumulated fatty acids 
could represent 1) a pathological accumulation of VLCFAs directly causing cellular 
dysfunction or 2) a byproduct of the affected pathway marking dysfunction but not 
participating in it.  To differentiate between these scenarios, we sought to test the 
consequences of varying levels of available VLCFAs on neuromaintenance.  We 
reasoned that if the neurodegeneration we observe in our ACSL-pathway mutants was 
due to a toxic accumulation of VLCFAs, increasing dietary intake of VLCFAs should 
exacerbate the neurodegeneration phenotype (Fig. 3.4 A). Therefore, we measured the 
extent of neurodegeneration in mutant animals fed a diet high in long chain fatty acids 
(which has been previously shown to impact lipid composition in Drosophila head tissue) 
compared to those fed a standard yeast diet (Carvalho et al., 2012). We found that the 
long chain fatty acid diet did not exacerbate retinal neurodegeneration (Fig. 3.4B-D vs E-
G).  These data suggest that an accumulation of long-/very long-chain fatty is unlikely to 
be the cause of disrupted neuromaintenance. 
An alternative model is that neurodegeneration in ACLS mutants might be due to 
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the lack of terminally processed fatty acid products. To test this hypothesis, we fed 
animals a diet high in medium chain fatty acids (7% coconut oil) from day 0-20, post-
eclosion.  Medium chain fatty acids can be activated by other chain-length specific ACSs, 
making them available substrate for a four-step elongation process to provide activated 
long-/very long-chain fatty acids. By feeding bgm and dbb mutants excess medium chain 
fatty acids, we hypothesized enough long/very long-chain fatty acids could be 
synthesized to fulfill cellular requirements, thus bypassing the genetic block to activating 
LC/VLCFA products in bgm and dbb mutant animals.  Indeed, we found feeding animals 
a diet high in medium chain fatty acids significantly reduced the retinal defects observed 
at day 20 post eclosion in both bgm and dbb animals (fig4H-J vs E-G)(bgm ND vs bgm 
MCD p<0.01; dbb ND vs dbb MCD p<0.05).  These data suggest a lack of an essential 
fatty acid product(s) causes defects in the ability of bgm and dbb animals to maintain 
basal neuromaintenance.   
As an extension of this idea, we asked whether artificially decreasing the cellular 
requirement for terminally processed fatty acid product could rescue the 
neurodegeneration seen in animals harboring a genetic block in L/VLCFA activation. 
Therefore, we used restricted application of visible light, a well-characterized 
environmental factor, to decrease the cellular demand for VLCFAs in bgm and dbb 
animals.  When animals were raised from day 0 to day 20 post-eclosion in darkness 
compared to the normal 12 hours alternating light/dark (control), we observed a 
significant reduction of neurodegeneration (Fig. 3.5B,C vs E,F).  We also observed a 
significant exacerbation of neurodegeneration in animals raised in 24-hour light 
conditions compared to 12 hours alternating light/dark (Fig. 3.5H,I vs E,F).  Importantly, 
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we also observed an increase in retinal defects in wild-type animals exposed to 24 hours 
of light compared to 12 hours alternating light/dark (Fig. 3.5G).  Defining the defect in 
wild-type animals as the amount of neurodegeneration which can be attributed solely to 
the environmental stress of constant light allowed us to determine that the worsening of 
neurodegeneration that we observe in bgm or dbb animals is more than expected if the 
genetic and environmental contributions to neurodegeneration were simply additive (Fig. 
3.5J, and data not shown).  Thus, we found modulating the cellular requirement for 
activated fatty acid products through stress modifies the defects in neuromaintenance in 
bgm and dbb animals, further indicating that neurodegeneration results from a lack of 
activated fatty acid product(s).  
That bgm and dbb animals fail neuromaintenance through a lack of vital fatty acid 
products despite input from elongation (Fig. 3.4A) suggests that input from both the 
activation pathway as well as the elongation pathway is required to maintain 
neuromaintenance.  In that case, a block in the elongation pathway should also result in 
neurodegeneration.  We used BLAST to identify four Drosophila elongases; only one of 
these, CG2781, is expressed in a spatial and temporal manner based on FlyAtlas RNA 
seq data and modENCODE (Flybase).  There are no genetic mutants described for this 
gene, so we tested the tissue specific requirements by using RNAi-mediated disruption.  
We found ubiquitous knockdown resulted in lethality before eclosion, suggesting that 
CG2781 is required for viability of adult Drosophila (data not shown).  Consistent with 
our previous data supporting a requirement of the ACSL pathway in neurons, we 
observed holes and disrupted pigment cells in the retina very similar to what we observed 
for bgm and dbb animals when we expressed CG2781-RNAi under the neuronal drivers 
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sim and elav (Fig. 3.6B,C).  Driving CG2781-RNAi under the glial driver repo resulted in 
slight retinal defects that were notable, but not statistically significantly different to 
+/UAS-CG2781-RNAi animals alone (Fig. 3.6D)(p=0.1067).  Taken together, results 
from diet, light and elongase studies point to a lack of terminally activated fatty acid 
product(s) as causative of neurodegeneration—the level of which, in wild-type animals, 




ALD is a neurodegenerative disease with mechanistic roots in altered lipid 
metabolism.  That this disease resides in a family of disorders (leukodystrophies) we 
incompletely understand and that there are other lipid-mediated neurodegenerative 
diseases (Fabry’s disease, Farber’s disease, Niemann Pick disease) puts our model in a 
unique position to provide much-needed information regarding lipid metabolism 
requirements in the nervous system.  In order to more fully understand the etiology of 
ALD, and the role of ACSL pathway in neuromainenance, we first sought to determine 
the tissue specificity of proteins that act in this pathway.  Broadly, there are two nervous 
system cell types—neurons and glia—and defects in both have been implicated in the 
pathology of leukodystrophies such as ALD (Kemp et al., 2012).  Determining if the 
primary cellular dysfunction occurs in one or both of these cell types in each disease will 
assist in pinpointing the fundamental defect leading to neurodegeneration. This goal has 
remained elusive due to several complicating factors, one of which is the activity of other 
tissue types such as the immune system, which rapidly escalates white matter 
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degeneration thus complicating study with secondary and tertiary insults (Eichler and 
Van Haren, 2007).  Information about tissue-specific etiology also influences treatment 
of these diseases, as therapeutic strategies are often influenced by which cell types are 
targeted (Drinkut et al., 2012). Previous observations of cell-type specificity using whole-
mount immunohistochemistry directed to ALDP (the protein product encoded by 
ABCD1) in both mouse (Fouquet et al., 1997) and human tissues (Fouquet et al., 1997; 
Hoftberger et al., 2007) have demonstrated that this protein is expressed in at least 
neuronal and glial cell types.  Höftenberger et al. additionally reports expression in non-
neuronal human tissues.  This broad expression profile seems to be conserved in 
Drosophila as dABCD1 appears to have moderate to high expression in most tissues 
tested (FlyAtlas, MODENCODE, FlyBase).  Given that glia and neurons share a close 
biological relationship, however, resolving tissue specificity to a more precise cell type 
requires the molecular tools of tissue-specific drivers.  Drosophila have demonstrated 
exceptional utility in this regard and given our previous characterization of the bgm and 
dbb single and double mutant animals as additional models for ALD, we utilized our 
newly described models to answer such fundamental questions.   
Here we present our findings that dABCD1 and at least one other member of the 
ACSL pathway—bgm—is functionally required in neuronal cells in the adult Drosophila 
retina. Using tissue-specific expression techniques, we show that expression of bgm in 
neuronal cells, but not in glial cells is sufficient to rescue neurodegeneration in a bgm 
mutant background.  Histologically, we initially observed that glial cells were affected 
prior to neuronal cells in ACSL mutants because structural aberrations disrupting these 
connections were the most visible and frequent.  However, in reviewing other retinal 
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degeneration mutants, we’ve observed that rhabdomere disruption is often a result of a 
developmental defect and does not necessarily accompany all models of adult 
neurodegeneration (Gambis et al., 2011; Rogge et al., 1991).  In models where 
photoreceptor degeneration is observed, ultrastructural analysis and a far later time point 
is often required for phenotypic analysis (Li et al., 2010; Phillips et al., 2008).  We think 
this is reminiscent of human studies focusing on glial cell degeneration in ALD likely 
because these cells are more prominent in the white matter affected in the human brain 
(Aubourg and Dubois-Dalcq, 2000; Di Biase et al., 2004; Feigenbaum et al., 2000; 
Katsuragi et al., 1996; Khan et al., 1998).   
Next we used a bioinformatic approach to identify the Drosophila homolog of 
mammalian ABCD1 (called CG2316), which we propose to be called dABCD1. 
Ubiquitous RNAi-mediated silencing of dABCD1 yielded viable flies with a shared loss-
of-function phenotype of retinal holes seen in adult bgm and dbb mutants.  The viability 
of adult Drosophila despite ubiquitous dABCD1 knockdown mimics instances of human 
patients carrying loss-of-function alleles in the ABCD1 gene and further suggests that 
ABCD1 is not required for viability in either flies or humans. We next demonstrated, 
using tissue-specific GAL4, that this gene is also specifically required in the nervous 
system for neuromaintenance. Our findings demonstrate that two members of the ACSL 
pathway have important functions in neurons, implying disruption of this pathway is 
responsible for defects in neuromaintenance resulting in neurodegeneration.  Given the 
recapitulation of the ACSL requirement for neuromaintenance in Drosophila and data 
that accumulating VLCFAs may not be sufficient for degeneration, we used our model to 
investigate the subcellular defect leading to cell-autonomous neurodegeneration in 
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mutants with disrupted ACSL metabolism.  
ALD has long been hypothesized to be caused by a block in the VLCFA recycling 
pathway resulting in a toxic accumulation of VLCFAs.  The identification of ACS 
mutants in Drosophila sharing a loss of function phenotype expanded the molecular 
cause of accumulated precursor to additional members of the ACSL pathway. Due in part 
to a clear function for this family of enzymes, the realization that a block in fatty acid 
activation biochemically results in 1) an accumulation of inactivated fatty acid precursor 
as well as 2) a lack of activated and terminally processed product uncovered the potential 
hypothesis that depletion of an essential fatty acid product for use within the cell could 
also play a role in neurodegeneration.  Past studies attempting to look at the contribution 
of an accumulation of precursor vs. lack of product to neurodegeneration have 
unsuccessfully uncoupled the two components usually through complementing ABCD1 
gene function back to the cell (Shinnoh et al., 1995). The complementation of the wild-
type ABCD1 gene simultaneously clears the accumulation while providing product, 
maintaining the coupled nature of the metabolic reaction.  We hypothesized that since the 
contribution of either precursor vs. product to cause neurodegeneration has not been 
interrogated in ALD patients, neurodegeneration may be a result of a block of the lipid 
metabolic pathway such that the activated lipid products are unable to be synthesized and 
used in the cell.  Indeed, the presence of humans harboring ABCD1 mutations as well as 
increased VLCFA levels, but manifesting no obvious neurodegenerative phenotype, 
supports this latter hypothesis (Raymond et al., 2010; Steinberg et al., 1993; Weller et al., 
1992). Additionally, the dietary regime Lorenzo’s oil, which normalizes VLCFA levels in 
patients, is ineffective at halting or preventing progress of the disease (Aubourg et al., 
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1990; Moser et al., 2005; Poulos et al., 1994; van Geel et al., 1999).  Our bgm and dbb 
mutants provide a straightforward platform to determine the requirement of an ACSL 
product in neuromaintenance.   
We show that feeding animals a diet where the only FAs available are L/VLCFAs 
(overlapping with the FA chain length seen accumulating in bgm and dbb animals) is not 
sufficient to exacerbate neurodegeneration in bgm and dbb animals.  Alternately, animals 
fed a high fat diet with an abundance of fatty acids that can be used as substrates in the 
elongase pathway (a parallel path to generate activated fatty acids) significantly rescues 
the neurodegenerative phenotype.  Our conclusion from these studies is that an 
accumulation of L/VLCFA is not sufficient to cause neurodegeneration in adult 
Drosophila, and a lack of fatty acid product species may in fact represent the cellular 
defect resulting in neurodegeneration.  
Diet studies, although useful, come with inherent complications as one attempts to 
track their metabolites through the maze of biological pathways.  Therefore, we 
approached the cellular cause of neurodegeneration with the logic that if a lack of 
terminally processed lipid was responsible for neurodegeneration, modulating the 
demand for this potentially vital product might represent an environmental modifier of 
our phenotype.  By using alternative light cycles to either increase (constant light) or 
decrease (constant dark) demand for terminally processed FAs demonstrates that not only 
that increasing the demand for product exacerbates neurodegeneration in bgm and dbb 
animals, but that decreasing the cellular demand alleviated neurodegeneration to near 
complete rescue.  While these data support that a lack of product for use within the cell is 
the primary cellular defect resulting in neurodegeneration, future studies will be required 
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to further delineate which potential uses of lipids are more important to this phenotype: 
membrane turnover, signaling transduction, or energy metabolism.   
Genetic null mutants in fatp, a dual fatty acid transporter and ACS, also have a 
retinal degeneration phenotype resulting from reduced rhodopsin signaling (Dourlen et 
al., 2012).  The authors hypothesize that this is due to altered membrane fluidics blocking 
internalization of activated Rh1 protein at the plasma membrane and resulting in cell-
autonomous neurotoxic activity.  Because of the dual function of Fatp, this effect could 
not be resolved to the transport or activation function.  Our results suggest 
neurodegeneration in fatp null mutants is due to the lack of ACS function, and 
reciprocally suggests that membrane fluidics in animals with a block in the ACSL 
pathway (bgm, dbb, or ABCD1) may represent the cellular use of the vital activated fatty 
acid product.  Indeed, long- and very long- chain fatty acids are unique in that they are 
used as components of membranes more frequently than other chain lengths of fatty acids 
(Kihara, 2012; Schneiter et al., 2004).  In addition, we hypothesize that our light 
manipulation studies may have a similar effect to other, naturally occurring 
environmental stresses such as trauma or epilepsy, which have previously been reported 
to exacerbate the clinical presentation of ALD (Raymond et al., 2010; Weller et al., 
1992). 
Our results also suggest a vital requirement of the elongase pathway in neuronal 
cells and that contribution by both the elongase and the ACSL pathways may be required 
to supply enough vital fatty acid product necessary for neuromaintenance. For instance, if 
bgm and dbb mutants represent only one arm of the path to supply a vital fatty acid 
product yet show a neurodegenerative phenotype, this suggests that input from both arms 
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of the ACSL pathway are required to supply the cell with enough activated fatty acid 
product.  We show that, in fact, blocking the input supplying product through the 
elongase pathway reveals a similar retinal degeneration phenotype seen in previous 
genetic blocks in the activation arm of the ACSL pathway.   
In conclusion, in this study, we have demonstrated that terminally processed 
L/VLCFA products of the ACSL pathway in neurons are required for neuromaintenance.  
This knowledge represents a huge leap in our understanding of ALD pathology and 
fundamentally shifts approaches to therapeutics by identifying neurons as a target tissue 
and suggesting that supplying a lacking cellular defect as opposed to removing an 
accumulation will yield successful therapies.  
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Figure 3.1 Neurodegeneration in bgm and dbb animals.  Images of plastic sections of 
wild-type (A), bgm (B), and dbb (C) adults at 20 days post-eclosion where disruption in 
the retinal pattern are evident in bgm and dbb mutants and appear as holes and disrupted 
pigment cells.  Aberrations are seen in some bgm (E) and dbb (F) adults but not in wild-
type adults (D) as early as 5 days post-eclosion.  No detection of aberrations in wild-type, 
bgm, or dbb animals is seen within 24 hours of eclosion (G-I).  Quantification on a 
neurodegeneration scale where 0=no neurodegeneration and 3=strongly affected (J). 
Scores were compared by one-way ANOVA with Dunnett’s posttest and p-values below 




Figure 3.2 Expression of bgm in adult retinal neurons is sufficient to rescue 
neuromaintenance in bgm animals. Representative cross-section of a bgm mutant at day 
20 post-eclosion (A).  Ubiquitous expression of an inducible bgm construct with tubulin-
GAL4 rescues neurodegeneration in a bgm mutant background (B). Driving expression in 
glial cells (repo) does not result in rescue (C); however the neuronal driver single-minded 
(sim) does rescue (D). DJ667 was used as a negative control as it is specifically expressed 
in flight muscles and fails to rescue (E).  Quantification of neurodegenerative phenotype 
(F). Scores were compared by one-way ANOVA with Dunnett’s posttest and p-values 
below 0.5 were determined significant. ***p<0.001. 
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Figure 3.3  The Drosophila homolog of ABCD1 is required for neuromaintenance. 
Retinal cross sections of a tubulin-GAL4/+ (A), and driver-less UAS-CG2316-RNAi 
control animals (B).  Ubiquitous knockdown of dABCD1 results in a shared loss-of-
function phenotype with bgm and dbb mutants (C).  Neuronal knock-down of dABCD1 
(D, E) but not glial knock-down (F) recapitulates neurodegeneration. Quantification of 
neurodegenerative phenotype A-F (G). Scores were compared by one-way ANOVA with 
Dunnett’s posttest and p-values below 0.5 were determined significant. ***p<0.001 
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Figure 3.4 Neurodegeneration in bgm and dbb animals is caused by a lack of 
activated fatty acids.  Two pathways converge to produce activated long-/very long-
chain fatty acid products within cells (A). Dietary supplementation of either long or 
medium chain lengths of fatty acids were used to test if an accumulation of fatty acids in 
bgm and dbb animals is causative of neurodegeneration.  Animals fed a diet where the 
only fatty acids are long (LD) did not experience a worsening of neurodegeneration (B-D 
vs E-G).  Animals fed an excess of medium chain fatty acids (MD) as substrate for the 
elongase pathway showed an alleviation of neurodegeneration (H-J vs E-G).  
Quantification of neurodegeneration in animals on a normal diet versus a long chain diet 
(K) and a medium chain diet (L). Scores were compared by one-way ANOVA with




Figure 3.5 Modulation of the demand for activated fatty acids modifies bgm and dbb 
neurodegeneration.  Cross sections of animals exposed to decreased light at zero hours 
of light/day (A-C), standard light at 12 hours of light/day (D-F), and increased light at 24 
hours of light/day (G-I). Quantification of neurodegenerative phenotype (J). Scores were 
compared by one-way ANOVA with Dunnett’s posttest and p-values below 0.5 were 
determined significant. ***p<0.001 
125
126
Figure 3.6  Decreasing the amount of fatty acid product by knocking down input 
through the elongase pathway also results in neurodegeneration.  Expression of 
RNAi targeting the Drosophila elongase CG2781 in neuronal cells results in a shared loss 
of function phenotype with bgm and dbb animals (B,C).  Quantification of 
neurodegenerative phenotype (E). Scores were compared by one-way ANOVA with 








































































 This chapter describes three experiments that are beyond the scope of primary 
dissertation research.  Results from these experiments were of limited use as they are 
focused on narrow hypotheses.  Reported here, they serve two purposes: to make this 
dissertation comprehensive of the work I undertook in the Letsou lab, and to serve as a 
potential launching pad for future lab members.  Thus, these three experiments represent 
mere observations that should thoroughly be tested, but nonetheless considered as the 
model for the mechanism of neurodegeneration in bgm and dbb mutants evolves.  
First, data in previous chapters of this dissertation have suggested a requirement 
in neuronal cells for a terminally processed activated fatty acid product in 
neuromaintenance in adult Drosophila.  However, the specific identity and cellular use of 
this fatty acid are so far unknown.  In this chapter, I will provide preliminary evidence 
pointing to one cellular pathway in which the terminally processed fatty acid functions.  
These studies have a particular relevance to therapeutic strategies as well as 
understanding the biological requirements of the nervous system. 
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The simplest explanation for the requirement of ASCL pathway members in 
neuromaintence would predict expression of bgm and dbb in neuronal tissue.  Indeed, in 
Chapter 3, I show a requirement of bgm in neuronal tissue for maintenance of retinal 
structure in adult Drosophila.  In this chapter, I determined bgm and dbb are expressed in 
adult Drosophila retinal tissue. However, resolution to expression in either glial or 
neuronal cells is difficult to resolve given the methods used.  Nonetheless, both bgm and 
dbb appear to be expressed in tissues in the retina, possibly consistent with a neuronal 
requirement of these genes. 
Second, lipids play three major roles within cells: as components of membranes, 
as energy substrates, and as mediators in signaling cascades (Schmitt et al., 2014).  All of 
these roles need to be fulfilled for all cells. However, it is unknown if nervous tissue 
possesses a particular sensitivity to some of these uses.  Without fully answering this 
question, there are examples of neurodegenerative models that result from a defect in 
some of these particular pathways discussed below.  
Energy utilization represents a well-known tissue-specific cellular requirement.  
In addition to tissue specific requirements of absolute energy consumption (Wang et al., 
2010), tissues can also show a specific requirement for energy substrates.  With regard to 
nervous tissue, it has long been known that glucose is the sole energy substrate used by 
the brain (Siegel, 1999).  Initial studies of this kind were done by measuring 
arteriovenous differences for various metabolites (Greger and Windhorst, 1996) and 
bolstered, still early on, by determining the respiratory quotient of brain tissues to be 
equal to 1.0—the value rendered when glucose is solely used as a substrate (Dickens, 
1936).  Although it is widely accepted that the brain only utilizes glucose for energy, it is 
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important to note that finer resolution of neuronal and glial energy utilization and intra-
tissue signaling is an ongoing area of research with continued capacity to inform 
neurometabolic disease (Belanger et al., 2011).   
With regard to this dissertation, due to the known use of glucose as the energy 
substrate used by neuronal tissues, it is unlikely that terminally processed fatty acid 
product(s) deficient in bgm and dbb single and double mutant animals impacts energy 
production.  However, the possibility remains that mitochondria still lie at the heart of 
neurodegeneration in these animals, as mitochondria not only represent a hub of energy 
metabolism but also important signaling molecules.  In this chapter, I report initial 
investigations into the role mitochondria play in ASCL-mediated neurodegeneration.  I 
test whether mitochondria play a cellular role in neurodegeneration by testing whether 
mitochondrial stress in the form of hyperoxic conditions exacerbates bgm and dbb single 
and double mutant animals to defects in neuromaintenance. 
Finally, cellular membranes are increasingly being recognized for their complex 
composition and their ability to affect signaling. For this reason, it is often difficult to 
parse membrane-signaling defects, in particular when signaling molecules are 
components of cellular membranes, such as phospholipase C (PLC).  PLC is a conserved, 
core molecule in the cellular response to light.  Exposure to light first induces a 
conformational change in the photopigment Rhodopsin that in turn activates a 
heterotrimeric G protein.  Release of the Gα subunit leads to activation of PLC, an 
integral membrane protein that cleaves the phospholipid phosphatidylinositol 4,5-
bisphosphate (PIP2) into two second messengers and releases a proton, soluble inositol 
1,4,5-triphosphate (IP3), and diacylglycerol (DAG).  DAG and IP3 both independently 
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activate protein kinase C (DAG directly, IP3 via release of intracellular Ca2+ pools), and 
this further transduces the signal within the cell.  PLC activation also results in activation 
of transient receptor potential channels (TRP channels) that depolarize the photoreceptor 
cell and propagate activation through retinal tissue.  PLC is required for detection of light 
in Drosophila and loss-of-function alleles of norpA (the gene encoding PLC in 
Drosophila) represent some of the first identified light-sensitive mutants (Cosens and 
Manning, 1969).  Highlighting the intricate relationship between this important signaling 
molecule and plasma membrane architecture is the recent discovery that PLC activates 
TRP channels through rapid degradation of PIP2 into DAG, the latter of which occupies 
less space in the membrane than what PIP2 occupies.  The rapid decrease in occupied 
membrane space when PIP2 is converted to DAG leads to contraction of the plasma 
membrane and consequent mechanical activation of TRP channel activity (Hardie and 
Franze, 2012).  Although no mutations of human PLC have been identified (potentially 
due to its participation in many other signaling pathways), constitutively active variants 
of Rhodopsin are the most common cause of Autosomal Dominant Retinitis Pigmentosa 
which leads to overactive rhodopsin signaling resulting in cytotoxicity and 
neurodegeneration (Mendes et al., 2005).  
Drosophila harboring mutant clones of a null allele of fatp (fatpk10307) suffer from 
neurodegeneration. The postulated mechanism leading to neurodegeneration is cell-
autonomous cytotoxicity as Rh1 is reported to accumulate in fatp mutants and dominant 
negative alleles of rhodopsin 1 as well as arrestin fully rescue degeneration in these 
animals (Dourlen et al., 2012).  Due to the dual nature of Fatp as both a fatty acid 
transport protein and an acyl CoA synthetase, however, the cytotoxic defect could not be 
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narrowed to a single function of Fatp.  In this chapter, I present preliminary evidence that 
rhodopsin accumulates in bgm and dbb mutants. However, different experiments are 
required to determine if this is a secondary effect of dysfunctional cells or a primary 
cause of dysfunction.  
 
Materials and Methods 
In situ hybridizations 
In situ hybridizations were performed on cryosections of whole animal adults. 
Briefly, adult males were embedded in 7.5% gelatin, 15% glucose, flash frozen in liquid 
nitrogen and sectioned at a thickness of 10 μM.  After sectioning, samples were 
immediately transferred to dry ice chambers to preserve RNA.  bgm and dbb probes were 
made using the following primers: bgmF 5’-CATTAGGCGGGTTAAATTCCCG-3’  
bgmR 5’-GTCGACGTTAGAACGCGGCTAC-3’, dbbF 5’-
TTGTAAAACGACGGCCAGTGA-3’ dbbR 5’- 
GGAAACAGCTATGACCATGATTACGC-3’ incorporating digoxygenin. Sequences 
are present in WT animals and either not present in mutants or present at very low levels 
(bgm mutant retains ~1% that of wild type ).  Hybridizations were performed as 
previously described (Wülbeck and Helfirch-Forster, 2007) and modified slightly for 
cryosections instead of whole mount tissue.  Samples were imaged using a Zeiss 
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Western blots 
Eclosed males were collected over a 24-hour period and aged for the times 
indicated. An average of 10 heads were isolated on ice in Laemmli buffer (10%glycerol, 
pH6.8 0.5M Tris, 10% SDS, 1% bromophenol blue, 1% β-mercaptoethanol, 100mM 
DTT) at a concentration of 1 head/3ul buffer, homogenized, and centrifuged for 30 
minutes at 12,000xg at room temperature.  Supernatant was collected and boiled for 5 
minutes before storage at -20oC or loading on a 12% acrylamide gel and transferred onto 
Immobilon-FL (Millipore).  Anti-Rh1 (1/1000, 4C5, DSHB) and anti-β-actin (1/1000, 
Novus Biologicals) were incubated overnight at 4oC before the appropriate secondary 
anti-mouse and anti-rabbit antibodies (1/10000, IRDye 680T and 800CW, LI-COR) were 
then incubated for 1 hour at room temperature. Protein bands were detected and 
quantified by infrared using a LI-COR Odyssey Infrared Imager and Odyssey software.  
Sample isolation was performed consistently between the hours of 12p-5pm to minimize 
a bias of Rh1 expression before exposure to daily light.  
 
Hyperoxic chamber 
Male flies were collected within 24 hours of eclosion, transferred to vials at a 
density of approximately 20 flies/vial, and housed in a humidified hyperoxic chamber 
maintained at 88% O2.  Dead animals were assayed daily and a vial change was 
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Results 
 To test the hypothesis that the ACSL pathway is required cell autonomously for 
neuromaintenance, I assayed bgm and dbb expression in the adult Drosophila head.  bgm 
expression was restricted to minimal retinal staining, a defined stripe at the fenestrated 
membrane, and peripheral staining around the medulla (Fig. 4.1A-B).  dbb, on the other 
hand, is expressed more broadly across the retina and central brain (Fig. 4.1C-D).  Using 
this method, it is difficult to determine which nervous tissue (neuronal or glial-like 
pigment cells) expresses bgm. However, the rescue experiments performed in Chapter 3 
suggest neuronal expression.  It is likely that both neuronal and glial cells express dbb.  
 Mitochondria play a role in mediating cell death and swollen mitochondria were 
observed in electron microscopy images in bgm dbb mutant animals (Sivachenko, 
unpublished).  To determine whether mitochondria play a central role in 
neurodegeneration in bgm and dbb single and double mutants, we raised animals in a 
hyperoxic environment and assayed whether mitochondrial stress exacerbates the slight 
but significant lifespan defect in mutant animals (Freeman and Crapo, 1981).  We saw an 
equivalent effect on the lifespan in wild type and all mutant animals (Fig. 4.2). Thus it is 
unlikely that mitochondria likely do not play a central role in neuronal dysfunction 
leading to cell death in ACSL mutants.  It should be acknowledged that hyperoxic stress 
represents one among many methods to test mitochondrial involvement and results from 
this study alone do not disprove the hypothesis.  These studies should be confirmed with 
finer tests of mitochondrial function discussed later in this chapter.  
 Lastly, given the proposed role of Fatp (another ACS in Drosophila) in 
neuromaintenance, we examined whether our ACSL mutants similarly function through 
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rhodopsin to effect neurodegeneration.  It has been proposed that in fatp mutants, 
activated rhodopsin cannot be internalized for recycling thereby leading to excitatory cell 
death in neuronal cells of the adult retina (Dourlen et al., 2012).  As a first step to 
investigating this possibility in bgm and dbb mutants, we performed western blot analysis 
to assess if Rh1 is accumulating in bgm and dbb mutants as an initial test of a shared 
mechanistic pathway to neurodegeneration.  Dourlen et al. report a two-fold 
accumulation of Rh1 via western blot in pooled animals aged from day 1-11 post-
eclosion.  Analysis of our animals over a longer and more precise time course showed 
incomplete penetrance of accumulation in bgm animals, pointing to Rhodopsin either as 
an effector of disease as predicted to be the case for fatp, or as a marker of dying cells.  
We see no differences between wild type and mutant animals at 2 days post eclosion (Fig. 
4.3A).  At day 8, day 10 and days 22-25, some bgm samples appear to contain more 
rhodopsin than wild type animals.  A time point in the middle of this span (day 12), 
however, does not appear to have any samples with increased rhodopsin expression.  
Additionally, we observed increases much higher than two-fold resulting in an overall 
increase in the range of values observed.  Of note, at only the day 22-25 time point do 
dbb animals possibly contain more rhodopsin that wild type.  We conclude that at 
present, these results are inconclusive.  As mentioned, even if rhodopsin is accumulating, 
rescue studies would be needed to discriminate between its role as an effector or marker 
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Discussion 
Mitochondria play well-characterized roles in signaling, especially relating to cell 
death (Liu et al., 1996).  Our hyperoxic study suggests mitochondria do not play a role in 
cell death in bgm and dbb single and double mutant neurodegeneration.  This finding is 
consistent with conclusions derived in studies of ABCD1 protein-deficient mice where 
despite accumulation of VLCFAs in whole muscle homogenates mitochondrial function 
remains intact (Oezen et al., 2005).  Due to the pleiotropic nature of reactive oxygen 
species acting not only on mitochondrial proteins, but also on all molecules present in an 
organism, my experiment was poorly focused.  A better strategy might be inclusion of 
p35 in neuronal tissue to determine if autonomous inhibition of cell death rescues 
neurodegeneration (Hay et al., 1994).  
Fatty acids compose cellular membranes, act as signaling molecules, and act as 
substrates for energy metabolism.  Identifying which of these general cellular causes 
leads to disease represents an important first step in our understanding of neuronal 
requirements of lipids and will inform the efficient design of reliable diagnostics and 
therapies for ALD.  Due to the known role of glucose and not fatty acids as the only 
energy substrate in the brain, which is almost completely nervous tissue, we speculated 
that degeneration in ACSL likely results from loss of a lipid-dependent signaling 
molecule or membrane component. Studies on phospholipase C suggest that in fact, these 
two cellular roles, at least in light-sensing photoreceptor cells, might represent a single 
defect (Hardie and Franze, 2012).   
We initiated inquiry into whether bgm and dbb mutants shared a mechanism for 
neurodegeneration suggested by experiments using null mutants of fatp.  Our hypothesis 
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of shared mechanism was founded in the shared function of both genes as ACSs as well 
as the shared neurodegenerative loss of function phenotype, and similar phenotypic 
dependencies on light exposure.  
We concluded through these studies that Rh1 might be accumulated in bgm but 
not dbb mutants after approximately 8 days post-eclosion. Therefore, we cannot exclude 
the hypothesis that degeneration seen in bgm mutants is due to a defect in Rh1 signaling. 
However, further confirmation of this mechanism of neurodegeneration must be 
performed.  
Retinal degeneration in null fatp mutants is cell autonomous, light dependent, and 
is reported to be rescued by a vitamin-A deficient diet. Vitamin A is the precursor for the 
rhosopdin chromophore and a vitamin A deficient diet rescues other retinal degeneration 
mutants in the genes retinal degeneration B, crumbs, and arrestin (arr) (Alloway et al., 
2000; Harris and Stark, 1977; Johnson et al., 2002).  The authors further support this 
notion by showing that over-expression of rh1 in photoreceptors is sufficient for 
neurodegeneration.  Molecularly, once rhodopsin receptors are activated, arrestin binds to 
an internal fragment and signals endocytosis of the activated receptor thereby quenching 
the excitatory signal and restoring the cell to a basal primed signaling state.  Stabilization 
of an arrestin/rh1 complex leads to excitotoxic neurodegeneration (Chinchore et al., 
2009; Kiselev et al., 2000; Satoh and Ready, 2005).  To this point, fatp; arr2 retinas lost 
significantly less photoreceptors suggesting fatp-/- retinas degenerate due to an excitotoxic 
mechanism.  Experiments further testing whether the mechanism of neurodegeneration is 
shared between bgm and fatp null mutants will be discussed in Chapter 5.  
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Figure 4.1  bgm and dbb are expressed in the affected tissues of the adult retina. In 
situ hybridization of wild type and mutant animals with probes complementary to bgm 
(A) and dbb (B) transcript, respectively. bgm has a restricted staining that appears to be 
restricted to the basement membrane and around the medulla and possibly slight staining 
in the retina. dbb stains ubiquitously throughout the central brain and optic lobe in only 

























Figure 4.2  Hyperoxia does not exacerbate lifespan defects in bgm and dbb animals.  
Death curves for animals raised from day 1 in hyperoxic conditions (A) compared to 
normoxic conditions (B).  Error bars represent standard error of all biological replicates. 
Table showing the percent survival of each mutant normalized to the P50 of wild type in 
hyperoxia or normoxia shows no worsening lifespan when normalized to the hyperoxic 
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Figure 4.3  Rh1 expression is highly variable, but some bgm mutant samples display 
higher levels of Rh1 than seen in wild type.  Quantification of Rh1 monomer, dimer, 
and oligomer expression assayed by western blot in animals aged 2 (A), 8 (B), 10 (C), 12 
(D), and 22-25 (E) days post-eclosion.  Extensive variability is seen but some samples 
appear to contain higher than wild type levels of Rh1. Each animal is represented by a 
diamond while lines represent the average within each group.  Representative images of 
Rh1 oligomer visualized with anti-Rh1 and actin (loading control) in young (dpe2) and 
old (dpe25) male animals (F).  Red boxes indicate the area used for quantification using 
Odyssey software. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 ALD is a fatal, childhood neurodegenerative disease most commonly caused by 
mutations in the ABCD1 gene.  Inheritance of the same null alleles in family members 
exhibit incomplete penetrance and variable expressivity of phenotypes—suggesting 
environmental and/or genetic modifiers while also complicating mechanistic studies of 
the disease.  We have generated the only ALD animal model displaying the most severe 
aspect of ALD pathology—central nervous system degeneration.  We utilized this model 
as a tool to probe the requirements of lipids in neuromaintenance and to answer long-
standing questions regarding the mechanism of degeneration in ALD.  We investigated 
the tissue-specific requirements of the ACSL pathway, as well as the mechanism of cell 
death in neurodegeneration.   
 We determined that Drosophila bgm is required in neuronal cells, and that the 
defects in neuromaintenance observed in bgm and dbb single mutants are due to a lack of 
terminally processed fatty acid product.  We recapitulated the requirement of products 
derived from the ACSL pathway by driving RNAi-mediated knock down of a Drosophila 
elongase expressed in the adult retina and show a shared neurodegenerative defect that 
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also originates in neurons.  Finally, we provide preliminary evidence that the terminally 
processed lipid product required in bgm and dbb animals plays a role in the rhodopsin-
signaling cascade.  
 In this work, the most impactful finding translating to ALD is the suggestion that 
accumulating VLCFAs seen in both humans and Drosophila bgm dbb animals are not 
sufficient to cause disease and in fact, the lack of activated fatty acid product represents 
the true cause of cellular dysfunction.  Evidence for the insufficiency of the toxic 
accumulation model was present in multiple forms in the literature; however, no study 
had parsed an accumulation of VLCFAs separately from a cellular lack of activated fatty 
acid product.  As such, the hypothesis was tested here in multiple ways: 1) two diets, one 
designed to exacerbate the phenotype caused by an accumulation, and the other designed 
to provide an activated long/very long chain fatty acid product via another biochemical 
pathway; 2) environmental modulation of the requirement for product through rearing in 
darkness; and 3) restriction of the absolute amount of terminally activated product by 
blocking elongation of medium chain substrates using RNAi.  Results from each of these 
experiments pointed to a model where “activated” long/very long chain fatty acids are 
required in neuromaintenance in adult Drosophila.   
 As mentioned, ALD is not unique in its disease etiology, being rooted in defects 
in lipid homeostasis as are other neurodegenerative diseases linked to genes whose 
encoded proteins play key roles in lipid metabolism  (acid sphingomyelinase: Niemen 
Pick type A OMIM#257200, alpha-galatosidase A deficiency: Fabry disease 
OMIM#301500, and acid ceramidase: Farber’s disease OMIM#228000).  Although the 
three diseases referenced here are associated with an accumulation of lipid species 
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(sphingomyelin, globotriaosylceramide and ceramide, respectively), the mechanism of 
neuropathy is unknown (Ahmad et al., 2009; Madra and Sturley, 2010; Ries and Gal, 
2006; Schiffmann, 2006; Vazquez et al., 2012; Zhang et al., 2000).  Moreover, Fabry 
disease and Farber’s disease both display variable expressivity suggesting as-yet-
unidentified genetic and/or environmental modifiers, similar to ALD.  At least for 
Farber’s disease, intralysosomal ceramide accumulation is not correlated with cellular 
apoptosis in fibroblasts harboring a block in sphingolipid metabolism.  Investigators 
hypothesize the cause of neurodegeneration is downstream of ceramidase function 
(Tohyama et al., 1999).  The mechanism of disease is not likely shared between all of 
these lipid-mediated neurodegenerative diseases; however, that degeneration in our 
animal model of ALD is caused by a defect downstream of ACS function might provide 
some insight into mechanisms of lipid-mediated degeneration in several related 
conditions such as these.  
ALD is also part of a larger family of leukodystrophies. As a whole, this family of 
diseases remains poorly understood and the identification of novel cellular mechanisms 
for diseases such as ALD can assist in our understanding of all diseases in this family.  
Only half of the patients who present in the clinic with a leukodystrophy can actually be 
traced to a cause.  That a significant fraction of severely ill patients exist with no known 
cause underscores the need for increasing our basic understanding for the requirements of 
neuromaintenance.  Altered lipid homeostasis in ALD manifests as a leukodystrophy. 
Therefore, mutations in other genes in this pathway may play a role in uncharacterized 
leukodystrophies as well.  Further, these advances in the mechanistic understanding of 
neurometabolic disease are imperative to direct appropriate clinical therapies for ALD.   
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Use of the bgm dbb animal model also changes our perception of how current 
therapies for ALD work.  For example, either allogenic hematopoietic cell transplant 
(HCT) or autologous transplant with correction of the ABCD1 gene can halt 
neurodegeneration (Baumann et al., 2003; Cartier et al., 2009).  Although not yet clear 
why, it is thought that transplanted microglial cells express ABCD1, thereby replacing 
dysfunctional microglia and rescuing degeneration.  However, our bgm rescue 
experiment (Chapter 3) suggests the ACSL pathway is required in neuronal cells and not 
glial cells, thereby opening the possibility that HCT transplant halts neurodegeneration 
because it eliminates the ability of the immune system to rapidly exacerbate 
demyelination.  This suggests that a strong dampening of the immune system would be as 
effective as an immune transplant in patients (although the earlier would leave the patient 
in a vulnerable, nonideal immune-suppressed state).  Additionally, this suggests that 
autologous transplantations with lentivirally-transduced HCT to express wild-type 
ABCD1 is an unnecessary step that results in an outcome no better than immune 
suppression or allogenic transplants.  Indeed, autologous transplants have not yet been 
shown to be more effective than allogenic transplants (Cartier et al., 2012).   
The need for the biological lessons surrounding lipid requirements of the nervous 
system is dire.  We have used the bgm and dbb Drosophila model of ALD to address key 
questions not previously considered: regarding the tissue specific requirements of long 
and very long chain fatty acids and the cellular mechanisms of degeneration resulting 
from deficiencies in this pathway.  As is the beauty of scientific research, these studies 
have led us not only to answers, but to more questions as well.  It seems likely that the 




Subcellular pathway requiring terminally processed 
long/very long chain fatty acid 
Dourlan and colleagues have suggested that the cytotoxic phenotype seen in 
mutants null for fatp is dependent on Rhodospin activation (Dourlen et al., 2012).  Since 
Rhodopsin synthesis can be halted with a diet deficient in vitamin A, it will be important 
to determine if this diet can rescue bgm and dbb mutant animals as it does animals with 
the null fatpk10307 allele.  Additionally, if degeneration in bgm and dbb animals is due to 
cytotoxic activation of photoreceptor cells leading to autonomous cell death as it is for 
animals with null alleles of fatp, a bgm arr1 or dbb arr1 mutant should rescue 
degeneration in these animals (alternatively the dominant negative allele of rhodopsin—
rh1G69D—can be used for double mutant analysis).  Determining if bgm and dbb mutant 
degeneration is due to an excitotoxic mechanism dually informs the mechanism of 
neurodegeneration in bgm and dbb mutants (excitotoxicity) as well as fatp mutants (likely 
due to ACS function).	  
 
Candidate Interacting Genes and Double Mutant Analysis 
Seizure or trauma 
To test the hypothesis that stress by use or by trauma can exacerbate 
neurodegeneration in tissues with defects in ACSL metabolism, Drosophila seizure-
sensitive mutants can be utilized.  I have generated four lines that carry the bang seizure-
sensitive allele of paralytic on the X chromosome and are either WT, or homozygous for 
bgm, dbb, or bgm dbb null alleles on the second chromosome.  parabss1 is a gain-of-
	  	  
151	  
function allele resulting from a missense mutation in the “paddle motif” which has been 
implicated in inactivation of the voltage-gated sodium channel Paralytic protein product 
(Parker et al., 2011). Hemizygous parabss1/Y males experience initial seizure, paralysis, 
and clonus-like seizures unique to bss1 alleles followed by a recovery seizure and 
recovery.  To test whether seizures represent an environmental (or sometimes genetic in 
the case of our PRRT2 allele in Chapter 2) modifier of the ACSL-deficient 
neurodegeneration, a daily seizures regime from day 1 post-eclosion to day 20 post 
eclosion in A) parabss1/Y males should be compared to B) parabss1; bgm1 C) parabss1; dbb1 
D) parabss1; bgm1 dbb1 animals under the same regime.   
Alternatively, a recent publication describes a Drosophila model of traumatic 
brain injury that can be used to confirm results with the parabss1 experiments or to stand 
alone as support for the hypothesis that trauma can exacerbate neurodegeneration in bgm 
and dbb mutants (Katzenberger et al., 2013).  
 
ABCD1 and bgm, dbb in the ACSL pathway 
 It is of obvious interest to determine if bgm and dbb mutants reside in the same 
biochemical pathway as dABCD1 mutants. There are no described genetic mutants of 
dABCD1, although there are a few possibilities located in large-scale screens (alleles 
MI11268, f00836, 39C-34, and 5-HA-1572 in FlyBase).  However, observing an aged 
bgm; elav>ABCD1-RNAi (or the equivalent dbb, or bgm dbb animal) and comparing 
severity of neurodegeneration to the already-characterized genetic single mutants or an 
animal with only elav>ABCD1-RNAi would likely produce results that suggest ACSs and 
the ABCD1 transporter reside in the same linear pathway.  I would predict no worsening 
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of the phenotype in animals with disrupted dABCD1 and ACS function. 
 
Elongase- CG2781 
Similar to ABCD1, it would be of interest to determine if the bgm and dbb ACSs 
and elongases are, in fact, parallel pathways.  Similar to dABCD1, no genetic null alleles 
of CG2781 have been reported but there are a few p-element insertions that may disrupt 
gene function (alleles: c06208 and MI01455).  My model would suggest a retinal 
phenotype exists if these alleles are genetic null alleles.  If a retinal phenotype is 
identified and can be exacerbated ACS, CG2781 double mutant animals could be 
examined.  If no genetic mutant can be used ACS; neuronal-GAL4>CG2781-RNAi can be 
examined.  In contrast to my prediction for the genetic interaction of bgm and dbb with 
dABCD1, I would postulate that ACS, CG2781 mutants (either genetic or elongase-
RNAi) would have a worse phenotype than either of the single mutants suggesting these 
represent parallel pathways to generate the activated long/very long chain lipid product.  
Of note, CG2781 has been mentioned once in the literature as a gene that is upregulated 
in null mutants of the neuronally expressed transcription factor gene erect wing 
(Haussmann et al., 2008).  No further characterization was performed.  
One alternative to this experiment is the analysis using an allele of the only 
identified trans-enoyl reductase, Sc2, which encodes the terminal step of the four-step 
fatty acid elongation.  Two alleles of this gene exist: Sc205634 and Sc2EY02236.  Sc205634 is a 
putative null allele exhibiting larval lethality. Therefore, clonal analysis in a bgm and dbb 
mutant background will be required to observe retinal clones of bgm;Sc205634 ommatidia 
in adult flies.  I predict that given Sc2 catalyzes the terminal step to fatty acid elongation 
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and my data suggest input from both elongation and activation pathways are required for 
neuromaintenance, double mutant retinal clones will display a worse phenotype than ACS 
or Sc2 single mutants (Chen et al., 2010; Gambis et al., 2011).  The EY02236 allele is the 
result of a UAS element insertion at the endogenous locus and on its own results in a 
weak loss-of-function, but upon induction can be over expressed.  An alternative 
approach would be to determine if Sc2 expression is required in a bgm and dbb mutant 
background for animals to be rescued on the medium chain diet.  A medium chain diet 
ameliorated retinal degeneration in bgm and dbb animals through an abundance of 
substrate for the elongase pathway. I would hypothesize that expression of Sc2 is required 
for bgm and dbb mutant rescue on a medium chain diet and therefore disruption of Sc2 
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